{"parse":{"title":"Severe cutaneous adverse reactions","pageid":55941104,"revid":857229643,"text":{"*":"<div class=\"mw-parser-output\"><table class=\"infobox\" style=\"width:22em\"><tbody><tr><th colspan=\"2\" style=\"text-align:center;font-size:125%;font-weight:bold;background:#ccc\">Severe cutaneous adverse reactions</th></tr></tbody></table>\n<p><b>Severe cutaneous adverse reactions</b> or <b>SCARs</b> are a group of potentially lethal <a href=\"/wiki/Adverse_drug_reaction\" title=\"Adverse drug reaction\">adverse drug reactions</a> that involve the skin and mucous membranes of various <a href=\"/wiki/Body_orifice\" title=\"Body orifice\">body openings</a> such as the <a href=\"/wiki/Eye\" title=\"Eye\">eyes</a>, <a href=\"/wiki/Ear\" title=\"Ear\">ears</a>, and <a href=\"/wiki/Mucous_membrane_of_nose\" title=\"Mucous membrane of nose\">inside the nose</a>, <a href=\"/wiki/Oral_mucosa\" title=\"Oral mucosa\">mouth</a>, and <a href=\"/wiki/Lips\" class=\"mw-redirect\" title=\"Lips\">lips</a>. In more severe cases, SCARs also involves serious damage to internal organs. SCARs includes five syndromes: <a href=\"/wiki/Drug_reaction_with_eosinophilia_and_systemic_symptoms\" title=\"Drug reaction with eosinophilia and systemic symptoms\">Drug reaction with eosinophilia and systemic symptoms</a> (i.e. DRESS syndrome, also termed Drug-induced hypersensitivity syndrome [DIHS]); <a href=\"/wiki/Steven_Johnson_syndrome\" class=\"mw-redirect\" title=\"Steven Johnson syndrome\">Steven Johnson syndrome</a> (SJS); <a href=\"/wiki/Toxic_epidermal_necrolysis\" title=\"Toxic epidermal necrolysis\">Toxic epidermal necrolysis</a> (TEN), <a href=\"/wiki/Stevens%E2%80%93Johnson_syndrome#Classification\" title=\"Stevens\u2013Johnson syndrome\">Stevens-Johnson/toxic epidermal necrolysis overlap syndrome</a> (SJS/TEN); and <a href=\"/wiki/Acute_generalized_exanthematous_pustulosis\" title=\"Acute generalized exanthematous pustulosis\">Acute generalized exanthematous pustulosis</a> (AGEP). The five disorders have similar <a href=\"/wiki/Pathophysiology\" title=\"Pathophysiology\">pathophysiologies</a>, i.e. disease-causing mechanisms, for which new strategies are in use or development to identify individuals predisposed to develop the SCARs-inducing effects of specific drugs and thereby avoid treatment with them.<sup id=\"cite_ref-pmid28256714_1-0\" class=\"reference\"><a href=\"#cite_note-pmid28256714-1\">&#91;1&#93;</a></sup> <a href=\"/wiki/Maculopapular_rash\" title=\"Maculopapular rash\">Maculopapular rash</a> (MPR) is a less-well defined and benign form of drug-induced adverse skin reactions; while not classified in the SCARs group, it shares with SCARS a similar pathophysiology and is caused by some of the same drugs which cause SCARs.<sup id=\"cite_ref-pmid26553194_2-0\" class=\"reference\"><a href=\"#cite_note-pmid26553194-2\">&#91;2&#93;</a></sup>\n</p><p>Adverse drug reactions are major therapeutic problems estimated to afflict up to 20% of inpatients and 25% of outpatients. About 90% of these adverse reactions take the form of benign <a href=\"/wiki/Morbilliform\" title=\"Morbilliform\">morbilliform rash</a> <a href=\"/wiki/Drug_eruption\" title=\"Drug eruption\">hypersensitivity drug reactions</a> such as MPR. However, they also include more serious reactions: <b>a)</b> <a href=\"/wiki/Pseudoallergy\" title=\"Pseudoallergy\">pseudo-allergic</a> reactions in which a drug directly stimulates <a href=\"/wiki/Mast_cell\" title=\"Mast cell\">mast cells</a>, <a href=\"/wiki/Basophils\" class=\"mw-redirect\" title=\"Basophils\">basophils</a>, and/or <a href=\"/wiki/Eosinophils\" class=\"mw-redirect\" title=\"Eosinophils\">eosinophils</a> to release pro-allergic mediators (e.g. <a href=\"/wiki/Histamine\" title=\"Histamine\">histamine</a>); <b>b)</b> <a href=\"/wiki/Type_I_hypersensitivity\" title=\"Type I hypersensitivity\">Type I</a>, <a href=\"/wiki/Type_II_hypersensitivity\" title=\"Type II hypersensitivity\">Type II</a>, and <a href=\"/wiki/Type_III_hypersensitivity\" title=\"Type III hypersensitivity\">Type III</a> hypersensitivity reactions of the <a href=\"/wiki/Adaptive_immune_system\" title=\"Adaptive immune system\">adaptive immune system</a> mediated by <a href=\"/wiki/IgE\" class=\"mw-redirect\" title=\"IgE\">IgE</a>, <a href=\"/wiki/IgG\" class=\"mw-redirect\" title=\"IgG\">IgG</a>, and/or <a href=\"/wiki/IgM\" class=\"mw-redirect\" title=\"IgM\">IgM</a> antibodies; and <b>c)</b> SCARs and MPR which are <a href=\"/wiki/Type_IV_hypersensitivity\" title=\"Type IV hypersensitivity\">Type IV hypersensitivity reactions</a> of the <a href=\"/wiki/Innate_immune_system\" title=\"Innate immune system\">innate immune system</a> initiated by <a href=\"/wiki/Lymphocytes\" class=\"mw-redirect\" title=\"Lymphocytes\">lymphocytes</a> of the T cell type and mediated by various types of <a href=\"/wiki/Leukocytes\" class=\"mw-redirect\" title=\"Leukocytes\">leukocytes</a> and <a href=\"/wiki/Cytokines\" class=\"mw-redirect\" title=\"Cytokines\">cytokines</a>.<sup id=\"cite_ref-pmid28345177_3-0\" class=\"reference\"><a href=\"#cite_note-pmid28345177-3\">&#91;3&#93;</a></sup>\n</p><p>Type IV hypersensitivity reactions are <a href=\"/wiki/Off-target\" class=\"mw-redirect\" title=\"Off-target\">off-target</a> drug reactions, i.e. reactions in which a drug causes toxicity by impacting a biological target other than the one(s) for which it is intended. They are <a href=\"/wiki/T_cell\" title=\"T cell\">T cell</a>-initiated <a href=\"/wiki/Delayed_type_hypersensitivity\" class=\"mw-redirect\" title=\"Delayed type hypersensitivity\">delayed hypersensitivity reactions</a> occurring selectively in individuals who may be predisposed to do so because of the genetically-based types of <a href=\"/wiki/Human_leukocyte_antigen\" title=\"Human leukocyte antigen\">human leukocyte antigens</a> (i.e. HLA) or <a href=\"/wiki/T-cell_receptor\" title=\"T-cell receptor\">T-cell receptors</a> they express; the efficiency with which they absorb, distribute to tissues, metabolize, and eliminate a drug or drug metabolite; or less well-defined idiosyncrasies.<sup id=\"cite_ref-pmid28256714_1-1\" class=\"reference\"><a href=\"#cite_note-pmid28256714-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-pmid28598363_4-0\" class=\"reference\"><a href=\"#cite_note-pmid28598363-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-pmid27960170_5-0\" class=\"reference\"><a href=\"#cite_note-pmid27960170-5\">&#91;5&#93;</a></sup>\n</p><p>SCARs are here considered as a group focusing on the similarities and differences in their pathophysiologies, clinical presentations, instigating drugs, and recommendations for drug avoidance. Further details on these syndromes can be found on their individual Wikipedia pages.\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#Disorders\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">Disorders</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-2\"><a href=\"#SJS,_TEN,_and_SJS/TEN\"><span class=\"tocnumber\">1.1</span> <span class=\"toctext\">SJS, TEN, and SJS/TEN</span></a></li>\n<li class=\"toclevel-2 tocsection-3\"><a href=\"#DRESS_syndrome\"><span class=\"tocnumber\">1.2</span> <span class=\"toctext\">DRESS syndrome</span></a></li>\n<li class=\"toclevel-2 tocsection-4\"><a href=\"#AGEP\"><span class=\"tocnumber\">1.3</span> <span class=\"toctext\">AGEP</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-5\"><a href=\"#Pathophysiology\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Pathophysiology</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-6\"><a href=\"#HLA_proteins\"><span class=\"tocnumber\">2.1</span> <span class=\"toctext\">HLA proteins</span></a></li>\n<li class=\"toclevel-2 tocsection-7\"><a href=\"#T_cell_receptors\"><span class=\"tocnumber\">2.2</span> <span class=\"toctext\">T cell receptors</span></a></li>\n<li class=\"toclevel-2 tocsection-8\"><a href=\"#ADME\"><span class=\"tocnumber\">2.3</span> <span class=\"toctext\">ADME</span></a></li>\n<li class=\"toclevel-2 tocsection-9\"><a href=\"#Other_factors\"><span class=\"tocnumber\">2.4</span> <span class=\"toctext\">Other factors</span></a>\n<ul>\n<li class=\"toclevel-3 tocsection-10\"><a href=\"#Virus_reactivation\"><span class=\"tocnumber\">2.4.1</span> <span class=\"toctext\">Virus reactivation</span></a></li>\n<li class=\"toclevel-3 tocsection-11\"><a href=\"#Infections\"><span class=\"tocnumber\">2.4.2</span> <span class=\"toctext\">Infections</span></a></li>\n<li class=\"toclevel-3 tocsection-12\"><a href=\"#Autoimmune_Disorders\"><span class=\"tocnumber\">2.4.3</span> <span class=\"toctext\">Autoimmune Disorders</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-2 tocsection-13\"><a href=\"#Effectors_of_tissue_injury\"><span class=\"tocnumber\">2.5</span> <span class=\"toctext\">Effectors of tissue injury</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-14\"><a href=\"#Prevention\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Prevention</span></a></li>\n<li class=\"toclevel-1 tocsection-15\"><a href=\"#References\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">References</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"Disorders\">Disorders</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Severe_cutaneous_adverse_reactions&amp;action=edit&amp;section=1\" title=\"Edit section: Disorders\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<h3><span id=\"SJS.2C_TEN.2C_and_SJS.2FTEN\"></span><span class=\"mw-headline\" id=\"SJS,_TEN,_and_SJS/TEN\">SJS, TEN, and SJS/TEN</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Severe_cutaneous_adverse_reactions&amp;action=edit&amp;section=2\" title=\"Edit section: SJS, TEN, and SJS/TEN\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Stevens%E2%80%93Johnson_syndrome\" title=\"Stevens\u2013Johnson syndrome\">Stevens\u2013Johnson syndrome</a></div>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Toxic_epidermal_necrolysis\" title=\"Toxic epidermal necrolysis\">Toxic epidermal necrolysis</a></div>\n<p>Stevens\u2013Johnson syndrome, toxic epidermal necrolysis, and Stevens\u2013Johnson syndrome/Toxic epidermal necrolysis overlap syndrome are a spectrum of Type IV, Subtype IVc, delayed hypersensitivity reactions, i.e. reactions initiated by CD8<sup>+</sup> T cells and <a href=\"/wiki/Natural_killer_T_cell\" title=\"Natural killer T cell\">natural killer T cells</a>.<sup id=\"cite_ref-pmid26553194_2-1\" class=\"reference\"><a href=\"#cite_note-pmid26553194-2\">&#91;2&#93;</a></sup> They are characterized initially by fever and flu-like symptoms followed within days by skin as well as <a href=\"/wiki/Mucous_membrane\" title=\"Mucous membrane\">mucous membrane</a> <a href=\"/wiki/Blister\" title=\"Blister\">blisters</a> and <a href=\"/wiki/Denudation\" title=\"Denudation\">denudation</a>. Differentiation of the three disorders is based on the extent of disease with SJS involving &lt;10%, SGS/TEN involving 10% to 30%, and TEN involving &gt;30% of the total bodily skin area. This spectrum of disorders is complicated by inflammation in and damage to internal organs such as the liver and, less commonly, kidney and heart. More importantly, they are also complicated by <a href=\"/wiki/Sepsis\" title=\"Sepsis\">sepsis</a> due to the loss of skin and mucous membrane epithelial barriers. In one study, SJS, TEN, and SJS/TEN mortality rates were  4.8%, 19.4%, and 14.8%, respectively, with an important portion of the deaths due to bacterial sepsis, particularly in the acute, early stage of these disorders.<sup id=\"cite_ref-pmid29188475_6-0\" class=\"reference\"><a href=\"#cite_note-pmid29188475-6\">&#91;6&#93;</a></sup><sup id=\"cite_ref-pmid28439852_7-0\" class=\"reference\"><a href=\"#cite_note-pmid28439852-7\">&#91;7&#93;</a></sup> The drugs most commonly triggering the SJS, TEN, and SJS/TEN spectrum of disorders are <a href=\"/wiki/Sulfonamide_(medicine)#Antimicrobials\" title=\"Sulfonamide (medicine)\">anti-infective sulfonamides</a>, <a href=\"/wiki/Anticonvulsant\" title=\"Anticonvulsant\">anticonvulsants</a> (e.g. <a href=\"/wiki/Carbamazepine\" title=\"Carbamazepine\">carbamazepine</a> and <a href=\"/wiki/Lamotrigine\" title=\"Lamotrigine\">lamotrigine</a>), non-steroidal anti-inflammatory drugs, <a href=\"/wiki/Allopurinol\" title=\"Allopurinol\">allopurinol</a>, <a href=\"/wiki/Nevirapine\" title=\"Nevirapine\">nevirapine</a>, and <a href=\"/wiki/Chlormezanone\" title=\"Chlormezanone\">chlormezanone</a>. Allopurinol appears in some studies to be the most common instigator of these disorders. Any new <a href=\"/wiki/Biological\" class=\"mw-redirect\" title=\"Biological\">biological</a> or <a href=\"/wiki/Herbalism\" title=\"Herbalism\">herbal remedy</a>, it is suggested, should be considered a possible cause of these disorders under the proper clinical circumstances.<sup id=\"cite_ref-pmid29188475_6-1\" class=\"reference\"><a href=\"#cite_note-pmid29188475-6\">&#91;6&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"DRESS_syndrome\">DRESS syndrome</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Severe_cutaneous_adverse_reactions&amp;action=edit&amp;section=3\" title=\"Edit section: DRESS syndrome\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/DRESS_syndrome\" class=\"mw-redirect\" title=\"DRESS syndrome\">DRESS syndrome</a></div>\n<p>The DRESS syndrome is a Type IV, Subtype IVb, hypersensitivity drug reaction, i.e. a reaction dependent on CD4(+) cells and the cell- and tissue-injuring action of eosinophils.<sup id=\"cite_ref-pmid26553194_2-2\" class=\"reference\"><a href=\"#cite_note-pmid26553194-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-pmid22794701_8-0\" class=\"reference\"><a href=\"#cite_note-pmid22794701-8\">&#91;8&#93;</a></sup> Skin lesions inflict 73% to 100% of afflicted individuals; they are generally infiltrative <a href=\"/wiki/Macules\" class=\"mw-redirect\" title=\"Macules\">macules</a> and <a href=\"/wiki/Cutaneous_condition#Lesions\" title=\"Cutaneous condition\">plaques</a>. About 75% of cases exhibit facial <a href=\"/wiki/Edema\" title=\"Edema\">edema</a>. The syndrome is also associated with other maladies caused by high levels of blood eosinophils such as the various <a href=\"/wiki/Hypereosinophilia\" title=\"Hypereosinophilia\">hypereosinophilia</a>-related disorders: persistent <a href=\"/wiki/Asthma\" title=\"Asthma\">asthma</a> and allergic <a href=\"/wiki/Rhinitis\" title=\"Rhinitis\">rhinitis</a> and, more significantly, eosinophil-based and lymphocyte-based inflammation of the liver (&gt;70% of cases), kidney (20% to 40% of cases), lung (~33% of cases), heart (4% to 27% of cases), and, uncommonly, the <a href=\"/wiki/Meninges\" title=\"Meninges\">meninges</a>, brain, gastrointestinal tract, and spleen.<sup id=\"cite_ref-pmid28598363_4-1\" class=\"reference\"><a href=\"#cite_note-pmid28598363-4\">&#91;4&#93;</a></sup> The disorder is lengthened and worsened in individuals that develop reactivation of <a href=\"/wiki/Virus_latency\" title=\"Virus latency\">latent viruses</a> of the <a href=\"/wiki/Herpesviridae\" title=\"Herpesviridae\">herpes viruses</a>.<sup id=\"cite_ref-pmid28598363_4-2\" class=\"reference\"><a href=\"#cite_note-pmid28598363-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-pmid28665896_9-0\" class=\"reference\"><a href=\"#cite_note-pmid28665896-9\">&#91;9&#93;</a></sup> The estimated mortality rate for the DRESS syndrome is about 10%. Allopurinol and sulfasalazine account for almost 66% of DRESS syndrome cases with <a href=\"/wiki/Minocycline\" title=\"Minocycline\">minocycline</a> being the third most common cause of the disorder; <a href=\"/wiki/Strontium_ranelate\" title=\"Strontium ranelate\">Strontium ranelate</a>, <a href=\"/wiki/Leflunomide\" title=\"Leflunomide\">leflunomide</a>, <a href=\"/wiki/Dapsone\" title=\"Dapsone\">dapsone</a>, and <a href=\"/wiki/Nonsteroidal_anti-inflammatory_drugs\" class=\"mw-redirect\" title=\"Nonsteroidal anti-inflammatory drugs\">nonsteroidal anti-inflammatory drugs</a> (<a href=\"/wiki/Diclofenac\" title=\"Diclofenac\">diclofenac</a>, <a href=\"/wiki/Celecoxib\" title=\"Celecoxib\">celecoxib</a>, <a href=\"/wiki/Ibuprofen\" title=\"Ibuprofen\">ibuprofen</a>, and <a href=\"/wiki/Phenylbutazone\" title=\"Phenylbutazone\">phenylbutazone</a>) are less common causes of the disorder.<sup id=\"cite_ref-pmid28138822_10-0\" class=\"reference\"><a href=\"#cite_note-pmid28138822-10\">&#91;10&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"AGEP\">AGEP</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Severe_cutaneous_adverse_reactions&amp;action=edit&amp;section=4\" title=\"Edit section: AGEP\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Acute_generalized_exanthematous_pustulosis\" title=\"Acute generalized exanthematous pustulosis\">Acute generalized exanthematous pustulosis</a></div>\n<p>AGEP is a rare <a href=\"/wiki/Type_IV_hypersensitivity\" title=\"Type IV hypersensitivity\">Type IV</a>, subtype IVd, hypersensitivity reaction dependent on neutrophils and characterized by the rapid formation of skin <a href=\"/wiki/Pustules\" class=\"mw-redirect\" title=\"Pustules\">pustules</a> on an <a href=\"/wiki/Erythematous\" class=\"mw-redirect\" title=\"Erythematous\">erythematous</a> background.<sup id=\"cite_ref-pmid26553194_2-3\" class=\"reference\"><a href=\"#cite_note-pmid26553194-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-pmid27472323_11-0\" class=\"reference\"><a href=\"#cite_note-pmid27472323-11\">&#91;11&#93;</a></sup> In one study of 28 patients, the disorder was complicated by involvement of the kidney (36% of cases), lung (27%), and liver (11%).<sup id=\"cite_ref-pmid28084022_12-0\" class=\"reference\"><a href=\"#cite_note-pmid28084022-12\">&#91;12&#93;</a></sup> It is the least severe of the SCARs disorders, typically shows a mild course, and is rarely associated with severe complications although <a href=\"/wiki/Superinfection\" title=\"Superinfection\">superinfection</a> of skin lesions may be life-threatening.<sup id=\"cite_ref-pmid26553194_2-4\" class=\"reference\"><a href=\"#cite_note-pmid26553194-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-pmid28476287_13-0\" class=\"reference\"><a href=\"#cite_note-pmid28476287-13\">&#91;13&#93;</a></sup><sup id=\"cite_ref-pmid27472323_11-1\" class=\"reference\"><a href=\"#cite_note-pmid27472323-11\">&#91;11&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Pathophysiology\">Pathophysiology</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Severe_cutaneous_adverse_reactions&amp;action=edit&amp;section=5\" title=\"Edit section: Pathophysiology\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Individuals are predisposed to develop SCARs in response to a given drug based on the types of <a href=\"/wiki/Human_leukocyte_antigen\" title=\"Human leukocyte antigen\">human leukocyte antigen</a> (i.e. HLA) proteins and T cell receptors that they express; their ability to process an instigating drug or the drug's metabolite(s); and other less well-defined factors. These predispositions are a consequence of the HLA allele and T cell receptor variants that individuals express in their <a href=\"/wiki/Antigen_presentation\" title=\"Antigen presentation\">antigen presentation</a> immune pathways; their <a href=\"/wiki/ADME\" title=\"ADME\">ADME</a>, i.e. efficiency in <b>A</b>bsorbing, <b>D</b>istributing to tissues, <b>M</b>etabolizing, and/or <b>E</b>liminating a drug or drug metabolite; and other less well-defined factors.\n</p>\n<h3><span class=\"mw-headline\" id=\"HLA_proteins\">HLA proteins</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Severe_cutaneous_adverse_reactions&amp;action=edit&amp;section=6\" title=\"Edit section: HLA proteins\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Drugs can cause SCARs by subverting the <a href=\"/wiki/Antigen_presentation\" title=\"Antigen presentation\">antigen presentation</a> pathways which recognize and trigger immune responses to non-self <a href=\"/wiki/Epitopes\" class=\"mw-redirect\" title=\"Epitopes\">epitopes</a> (i.e. <a href=\"/wiki/Antigens\" class=\"mw-redirect\" title=\"Antigens\">antigens</a>) on foreign proteins. These proteins are taken up by <a href=\"/wiki/Antigen-presenting_cells\" class=\"mw-redirect\" title=\"Antigen-presenting cells\">antigen-presenting cells</a> (APC) and degraded into small <a href=\"/wiki/Peptide\" title=\"Peptide\">peptides</a>. The peptides are inserted into a groove on HLA proteins that are part of <a href=\"/wiki/Major_histocompatibility_complex\" title=\"Major histocompatibility complex\">major histocompatibility complexes</a> (i.e. MHC) and  presented to <a href=\"/wiki/T_cell_receptor\" class=\"mw-redirect\" title=\"T cell receptor\">T cell receptors</a> (TCR) on nearby <a href=\"/wiki/Cytotoxic_T_cells\" class=\"mw-redirect\" title=\"Cytotoxic T cells\">cytotoxic T cells</a> (i.e. CD8<sup>+</sup> T cells) or <a href=\"/wiki/T_helper_cells\" class=\"mw-redirect\" title=\"T helper cells\">T helper cells</a> (i.e. CD4<sup>+</sup> T cells). T cell receptors are heterologous; only a small fraction of them can bind a particular epitope on presented peptides and this binding is restricted to non-self epitopes. Upon binding a non-self epitope on a presented peptide, a T cell receptor becomes active in stimulating its parent cell to mount one of two types of immune responses based on whether the APC presenting the peptide is professional or non-professional in type. Non-professional APC include all nucleated cells; these cells load the processed peptides onto <a href=\"/wiki/MHC_class_I\" title=\"MHC class I\">MHC class I</a> (i.e. <a href=\"/wiki/HLA-A\" title=\"HLA-A\">HLA-A</a>, <a href=\"/wiki/HLA-B\" title=\"HLA-B\">HLA-B</a>, or <a href=\"/wiki/HLA-C\" title=\"HLA-C\">HLA-C</a>) proteins and thereon present the peptides to CD8<sup>+</sup> T cells. Those CD8<sup>+</sup> T cells whose T cell receptors bind an non-self epitope on the peptides are stimulated to attack cells or pathogens expressing this epitope. Professional APC are <a href=\"/wiki/Dendritic_cells\" class=\"mw-redirect\" title=\"Dendritic cells\">dendritic cells</a>, <a href=\"/wiki/Macrophages\" class=\"mw-redirect\" title=\"Macrophages\">macrophages</a>, and <a href=\"/wiki/B_cells\" class=\"mw-redirect\" title=\"B cells\">B cells</a>. They load processed peptides onto <a href=\"/wiki/MHC_class_II\" title=\"MHC class II\">MHC class II</a> (i.e. <a href=\"/wiki/HLA-DM\" title=\"HLA-DM\">HLA-DM</a>, <a href=\"/wiki/HLA-DO\" title=\"HLA-DO\">HLA-DO</a>, <a href=\"/wiki/HLA-DP\" title=\"HLA-DP\">HLA-DP</a>,<a href=\"/wiki/HLA-DQ\" title=\"HLA-DQ\">HLA-DQ</a>, or <a href=\"/wiki/HLA-DR\" title=\"HLA-DR\">HLA-DR</a>) proteins and thereon present the peptides to CD4<sup>+</sup> T cells. Those CD4<sup>+</sup> T cells whose T cell receptors bind a non-self epitope on presented peptides are stimulated to orchestrate <a href=\"/wiki/Helper_T_cell#Determination_of_the_effector_T_cell_response\" class=\"mw-redirect\" title=\"Helper T cell\">various immune reactions</a> that attack soluble proteins, pathogens, and host cells and tissues that express the non-self epitope. SCARs-inducing drugs can act through these pathways to cause CD8<sup>+</sup> or CD4<sup>+</sup> T cells to mount immune responses that are inappropriately directed against bodily tissues. Four models propose the underlying mechanisms by which SCARs-inducing drugs may activate T cells to mount immune responses against self:<sup id=\"cite_ref-pmid28345177_3-1\" class=\"reference\"><a href=\"#cite_note-pmid28345177-3\">&#91;3&#93;</a></sup><sup id=\"cite_ref-pmid28476287_13-1\" class=\"reference\"><a href=\"#cite_note-pmid28476287-13\">&#91;13&#93;</a></sup>\n</p>\n<ul><li><a href=\"/wiki/Hapten\" title=\"Hapten\">Hapten</a> model: A drug (here termed a <a href=\"/wiki/Hapten\" title=\"Hapten\">hapten</a>) <a href=\"/wiki/Covalent_bond\" title=\"Covalent bond\">covalently binds</a> to a host protein to create a non-self epitope; the protein is degraded in APC to drug-bound peptides which are loaded onto the groove in HLA proteins and then presented to T cells. Those T cells whose T cell receptors bind the drug-related epitope on a presented peptide are thereby activated.</li>\n<li>Pro-hapten model: This model is identical to the hapten model except that a drug's metabolite rather than the drug acts as the hapten that forms the non-self epitope.</li>\n<li>p-i Model: A drug or its metabolite fits into the groove in HLA proteins to become a non-self epitope which is presented to and activates T cells whose T cell receptors bind the drug-related epitope; alternatively, the drug binds to T cell receptors on and thereby directly activates the receptors' parent T cells.</li>\n<li>Altered peptide repertoire model: A drug or its metabolite binds directly to a HLA protein outside of its groove to alter the HLA protein's structure; the altered HLA protein thereby contains a non-self epitope which activates those T cells whose T cell receptors bind the drug-created epitope.</li></ul>\n<p>HLA genes are highly <a href=\"/wiki/Polymorphism_(biology)\" title=\"Polymorphism (biology)\">polymorphic</a>, i.e. have many different <a href=\"/wiki/Serotypes\" class=\"mw-redirect\" title=\"Serotypes\">serotypes</a> (i.e. <a href=\"/wiki/Alleles\" class=\"mw-redirect\" title=\"Alleles\">alleles</a>) while T cell receptor genes receptors are <a href=\"/wiki/Genome_editing\" title=\"Genome editing\">edited</a>. i.e. altered to encode proteins with different amino acid sequences. Humans, it is estimated, express more than 10,000 different HLA class I proteins, 3,000 different HLA class II proteins, and 100 trillion different T cell receptors. An individual, however, expresses only a fraction of these polymorphic or edited gene products. Since a SCARs-inducing drug interacts with only one or a few types of HLA proteins or T cell receptors, its ability to induce a SCARs disorder is limited to those individuals who express those HLA proteins that make the appropriate HLA/non-self peptide or the T cell that expresses the T cell receptor that recognize the non-self epitope created by the drug.<sup id=\"cite_ref-pmid28345177_3-2\" class=\"reference\"><a href=\"#cite_note-pmid28345177-3\">&#91;3&#93;</a></sup><sup id=\"cite_ref-pmid28476287_13-2\" class=\"reference\"><a href=\"#cite_note-pmid28476287-13\">&#91;13&#93;</a></sup> Thus, only rare individuals are predisposed to develop a SCARs disorder in response to a particular drug on the bases of their expression of specific HLA protein or T cell receptor types.<sup id=\"cite_ref-pmid27960170_5-1\" class=\"reference\"><a href=\"#cite_note-pmid27960170-5\">&#91;5&#93;</a></sup>\n</p><p>SCARs disorders are triggered by wide range of drugs<sup id=\"cite_ref-pmid28598363_4-3\" class=\"reference\"><a href=\"#cite_note-pmid28598363-4\">&#91;4&#93;</a></sup> with the most commonly reported offenders being <a href=\"/wiki/Carbamazepine\" title=\"Carbamazepine\">Carbamazepine</a>, <a href=\"/wiki/Allopurinol\" title=\"Allopurinol\">allopurinol</a>, <a href=\"/wiki/Abacavir\" title=\"Abacavir\">abacavir</a>, <a href=\"/wiki/Phenytoin\" title=\"Phenytoin\">phenytoin</a>, and <a href=\"/wiki/Nevirapine\" title=\"Nevirapine\">nevirapine</a>.<sup id=\"cite_ref-pmid28345177_3-3\" class=\"reference\"><a href=\"#cite_note-pmid28345177-3\">&#91;3&#93;</a></sup> These drugs evoke SCARs by interacting with one or just a few HLA proteins. The following table list drugs repeatedly implicated in eliciting SCARs; it also gives the drugs' therapeutic targets, HLA <a href=\"/wiki/Serotypes\" class=\"mw-redirect\" title=\"Serotypes\">serotypes</a> through which they act, the types of SCARs disorders they trigger, the negative and positive predictive values for the drugs (where known), and the populations afflicted.<sup id=\"cite_ref-pmid28256714_1-2\" class=\"reference\"><a href=\"#cite_note-pmid28256714-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-pmid28345177_3-4\" class=\"reference\"><a href=\"#cite_note-pmid28345177-3\">&#91;3&#93;</a></sup> <a href=\"/wiki/Positive_and_negative_predictive_values#Positive_predictive_value\" title=\"Positive and negative predictive values\">Positive predictive values</a> give the true percentages of individuals with the indicated HLA gene allele (identified as a <a href=\"/wiki/Serotype\" title=\"Serotype\">serotype</a>) that develop the cited drug-induced SCARs; <a href=\"/wiki/Positive_and_negative_predictive_values#Negative_predictive_value\" title=\"Positive and negative predictive values\">negative predictive values</a> give the percentage of individuals without the indicated serotype that fail to develop the cited drug-induced SCARs. For example, Chinese, Korean, Japanese, and European individuals that express the HLA-A31:01 allele have a 1% true chance of developing the DRESS syndrome while HLA-A31:01 negative individuals in these specific populations have a 99.9% true chance of not developing the DRESS syndrome when treated with carbamazepine. In this particular example, the HLA-A31:01 allele is virtually necessary but clearly not sufficient for developing the DRESS syndrome in response to carbamazepine. The table also shows that: positive predictive values lie between 0.59-55%, i.e. far below 100%; positive as well as negative predictive values vary with the population tested; a drug may cause more than one type of SCARs disorder or interact with more than one HLA serotype to cause SCARs; and the level of susceptibility to a drug varies between populations. These findings indicate that other factors, generally regarded as due to unspecified population-related genetic differences, contribute decisively to developing SCARs.<sup id=\"cite_ref-pmid28345177_3-5\" class=\"reference\"><a href=\"#cite_note-pmid28345177-3\">&#91;3&#93;</a></sup><sup id=\"cite_ref-pmid28598363_4-4\" class=\"reference\"><a href=\"#cite_note-pmid28598363-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-pmid28476287_13-3\" class=\"reference\"><a href=\"#cite_note-pmid28476287-13\">&#91;13&#93;</a></sup><sup id=\"cite_ref-pmid29333460_14-0\" class=\"reference\"><a href=\"#cite_note-pmid29333460-14\">&#91;14&#93;</a></sup>\n</p>\n<table class=\"wikitable\">\n<tbody><tr>\n<td>Drug</td>\n<td>Drug action</td>\n<td>HLA gene and allele</td>\n<td>SCARs disorder triggered</td>\n<td><a href=\"/wiki/Positive_and_negative_predictive_values#Positive_predictive_value\" title=\"Positive and negative predictive values\">Positive predictive value</a></td>\n<td><a href=\"/wiki/Positive_and_negative_predictive_values#Negative_predictive_value\" title=\"Positive and negative predictive values\">Negative predictive value</a></td>\n<td>Populations afflicted\n</td></tr>\n<tr>\n<td>Carbamazepine</td>\n<td><a href=\"/wiki/Anticonvulsant\" title=\"Anticonvulsant\">anticonvulsant</a></td>\n<td><a href=\"/wiki/HLA-A31#Serotype\" title=\"HLA-A31\">HLA-A*31:01</a></td>\n<td>DRESS syndrome</td>\n<td>1%</td>\n<td>99.9%</td>\n<td>Chinese, Koreans, Japanese, European\n</td></tr>\n<tr>\n<td>Carbamazepine</td>\n<td><a href=\"/wiki/Anticonvulsant\" title=\"Anticonvulsant\">anticonvulsant</a></td>\n<td><a href=\"/wiki/HLA-A31#Serotype\" title=\"HLA-A31\">HLA-A*31:01</a></td>\n<td>SJS, TEN, SJS/TEN</td>\n<td>0.89%</td>\n<td>99.98%</td>\n<td>European\n</td></tr>\n<tr>\n<td>Carbamazepine</td>\n<td><a href=\"/wiki/Anticonvulsant\" title=\"Anticonvulsant\">anticonvulsant</a></td>\n<td><a href=\"/wiki/HLA-A31#Serotype\" title=\"HLA-A31\">HLA-A*31:01</a></td>\n<td>SJS, TEN, SJS/TEN</td>\n<td>0.59%</td>\n<td>99.97%</td>\n<td>Chinese\n</td></tr>\n<tr>\n<td>Carbamazepine</td>\n<td><a href=\"/wiki/Anticonvulsant\" title=\"Anticonvulsant\">anticonvulsant</a></td>\n<td><a href=\"/wiki/HLA-A31#Serotype\" title=\"HLA-A31\">HLA-A*31:01</a></td>\n<td>SJS, TEN, SJS/TEN</td>\n<td>?</td>\n<td>?</td>\n<td>Northern European, Japanese, Korean\n</td></tr>\n<tr>\n<td>Carbamazepine</td>\n<td><a href=\"/wiki/Anticonvulsant\" title=\"Anticonvulsant\">anticonvulsant</a></td>\n<td><a href=\"/wiki/HLA-B15#Serotype\" title=\"HLA-B15\">HLA-B*15:02</a></td>\n<td>SJS, TEN, SJS/TEN</td>\n<td>3%</td>\n<td>100%</td>\n<td>Chinese, Tai, Malaysian, Koreans, Indian\n</td></tr>\n<tr>\n<td>Carbamazepine</td>\n<td><a href=\"/wiki/Anticonvulsant\" title=\"Anticonvulsant\">anticonvulsant</a></td>\n<td><a href=\"/wiki/HLA-A31#Serotype\" title=\"HLA-A31\">HLA-A*31:01</a></td>\n<td>MPE</td>\n<td>34/9%</td>\n<td>96.7%</td>\n<td>Han Chinese\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Oxcarbazepine\" title=\"Oxcarbazepine\">Oxcarbazepine</a></td>\n<td><a href=\"/wiki/Anticonvulsant\" title=\"Anticonvulsant\">anticonvulsant</a></td>\n<td><a href=\"/wiki/HLA-B15#Serotype\" title=\"HLA-B15\">HLA-B*15:01</a></td>\n<td>SJS, TEN, SJS/TEN</td>\n<td>?</td>\n<td>?</td>\n<td><a href=\"/wiki/Han_Chinese\" title=\"Han Chinese\">Han Chinese</a>, Taiwanese\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Phenytoin\" title=\"Phenytoin\">Phenytoin</a></td>\n<td><a href=\"/wiki/Anticonvulsant\" title=\"Anticonvulsant\">anticonvulsant</a></td>\n<td><a href=\"/wiki/HLA-B13#Serotype\" title=\"HLA-B13\">HLA-B*13:01</a> or <a href=\"/wiki/HLA-B15#Serotype\" title=\"HLA-B15\">HLA-B51:01</a></td>\n<td>DRESS syndrome, MPE</td>\n<td>?</td>\n<td>?</td>\n<td><a href=\"/wiki/Han_Chinese\" title=\"Han Chinese\">Han Chinese</a>\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Phenytoin\" title=\"Phenytoin\">Phenytoin</a></td>\n<td><a href=\"/wiki/Anticonvulsant\" title=\"Anticonvulsant\">anticonvulsant</a></td>\n<td><a href=\"/wiki/HLA-B15#Serotype:\" title=\"HLA-B15\">HLA-B*15:02</a>, <a href=\"/wiki/HLA-C#Nomenclature#C0*8\" title=\"HLA-C\">HLA-Cw*08:01</a>, or <a href=\"/wiki/HLA-DRB1\" title=\"HLA-DRB1\">HLA-DRB1*16:02</a></td>\n<td>DRESS syndrome</td>\n<td>?</td>\n<td>?</td>\n<td><a href=\"/wiki/Han_Chinese\" title=\"Han Chinese\">Han Chinese</a>\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Lamotrigine\" title=\"Lamotrigine\">Lamotrigine</a></td>\n<td><a href=\"/wiki/Anticonvulsant\" title=\"Anticonvulsant\">anticonvulsant</a></td>\n<td><a href=\"/wiki/HLA-B15#Serotype:\" title=\"HLA-B15\">HLA-B*15:02</a> or <a href=\"/wiki/HLA-B38\" title=\"HLA-B38\">HLA-B*38</a></td>\n<td>SJS, TEN, SJS/TEN</td>\n<td>?</td>\n<td>?</td>\n<td><a href=\"/wiki/Han_Chinese\" title=\"Han Chinese\">Han Chinese</a>\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Lamotrigine\" title=\"Lamotrigine\">Lamotrigine</a></td>\n<td><a href=\"/wiki/Anticonvulsant\" title=\"Anticonvulsant\">anticonvulsant</a></td>\n<td><a href=\"/wiki/HLA-B38\" title=\"HLA-B38\">HLA-B*38</a>, <a href=\"/wiki/HLA-B58#Serotype\" title=\"HLA-B58\">HLA-B*58:01</a>, or <a href=\"/wiki/HLA-A68#Allele_frequencies#:A*6801\" title=\"HLA-A68\">HLA:68:01</a></td>\n<td>SJS, TEN, SJS/TEN</td>\n<td>?</td>\n<td>?</td>\n<td>European\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Lamotrigine\" title=\"Lamotrigine\">Lamotrigine</a></td>\n<td><a href=\"/wiki/Anticonvulsant\" title=\"Anticonvulsant\">anticonvulsant</a></td>\n<td><a href=\"/wiki/HLA-C#Nomenclature#06\" title=\"HLA-C\">HLA-Cw*07</a>, <a href=\"/wiki/HLA-DQB1#Alleles\" title=\"HLA-DQB1\">HLA-DQB*06:09</a>, or <a href=\"/wiki/HLA-DRB1\" title=\"HLA-DRB1\">HLA-DRB1*13:01</a></td>\n<td>SJS, TEN, SJS/TEN</td>\n<td>?</td>\n<td>?</td>\n<td>European\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Oxicam\" title=\"Oxicam\">Oxicam</a></td>\n<td><a href=\"/wiki/Anti-inflammatory\" title=\"Anti-inflammatory\">anti-inflammatory</a></td>\n<td><a href=\"/wiki/HLA-B73\" title=\"HLA-B73\">HLA-B*73</a>, <a href=\"/wiki/HLA-A2\" class=\"mw-redirect\" title=\"HLA-A2\">HLA-A*2</a>, or <a href=\"/wiki/HLA-B12\" title=\"HLA-B12\">HLA-B*12</a></td>\n<td>SJS, TEN, SJS/TEN</td>\n<td>?</td>\n<td>?</td>\n<td>European\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Sulfonamide_(medicine)\" title=\"Sulfonamide (medicine)\">various sulfa drugs</a></td>\n<td><a href=\"/wiki/Antibiotic\" title=\"Antibiotic\">antibiotic</a></td>\n<td><a href=\"/wiki/HLA-Cw4\" title=\"HLA-Cw4\">HLA-Cw*4</a></td>\n<td>SJS, TEN, SJS/TEN</td>\n<td>?</td>\n<td>?</td>\n<td><a href=\"/wiki/Han_Chinese\" title=\"Han Chinese\">Han Chinese</a>\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Sulfonamide_(medicine)\" title=\"Sulfonamide (medicine)\">various sulfa drugs</a></td>\n<td><a href=\"/wiki/Antibiotic\" title=\"Antibiotic\">antibiotic</a></td>\n<td><a href=\"/wiki/HLA-B38\" title=\"HLA-B38\">HLA-B*38</a></td>\n<td>SJS, TEN, SJS/TEN</td>\n<td>?</td>\n<td>?</td>\n<td>European\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Methazolamide\" title=\"Methazolamide\">Methazolamide</a></td>\n<td>lowers <a href=\"/wiki/Intraocular_pressure\" title=\"Intraocular pressure\">intraocular pressure</a></td>\n<td><a href=\"/wiki/HLA-B59\" title=\"HLA-B59\">HLA-B*59:01</a> or <a href=\"/wiki/HLA-C#Nomenclature\" title=\"HLA-C\">HLA-CW*01:02</a></td>\n<td>SJS, TEN, SJS/TEN</td>\n<td>?</td>\n<td>?</td>\n<td>Korean, Japanese\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Dapsone\" title=\"Dapsone\">Dapsone</a></td>\n<td><a href=\"/wiki/Antibiotic\" title=\"Antibiotic\">antibiotic</a>, <a href=\"/wiki/Anti-inflammatory\" title=\"Anti-inflammatory\">anti-inflammatory</a></td>\n<td><a href=\"/wiki/HLA-B13#serotype\" title=\"HLA-B13\">HLA-B*13:01</a></td>\n<td>DRESS syndrome</td>\n<td>7.8%</td>\n<td>99.8%</td>\n<td><a href=\"/wiki/Han_Chinese\" title=\"Han Chinese\">Han Chinese</a>\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Allopurinol\" title=\"Allopurinol\">Allopurinol</a></td>\n<td><a href=\"/wiki/Gout\" title=\"Gout\">anti-gout drug</a></td>\n<td><a href=\"/wiki/HLA-B58#Serotype\" title=\"HLA-B58\">HLA-B*58:01</a></td>\n<td>DRESS syndrome, SJS, TEN, SJS/TEN</td>\n<td>3%</td>\n<td>100% in Han Chinese</td>\n<td><a href=\"/wiki/Han_Chinese\" title=\"Han Chinese\">Han Chinese</a>, Korean, Thai, European\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Nevirapine\" title=\"Nevirapine\">Nevirapine</a></td>\n<td><a href=\"/wiki/Anti-retroviral\" class=\"mw-redirect\" title=\"Anti-retroviral\">anti-retroviral</a></td>\n<td><a href=\"/wiki/HLA-DRB1\" title=\"HLA-DRB1\">HLA-DRB1*01:01</a> or <a href=\"/wiki/HLA-DRB1\" title=\"HLA-DRB1\">HLA-DRB1*01:012</a></td>\n<td>DRESS syndrome</td>\n<td>18%</td>\n<td>96%</td>\n<td>Australian, European, South African\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Nevirapine\" title=\"Nevirapine\">Nevirapine</a></td>\n<td><a href=\"/wiki/Anti-retroviral\" class=\"mw-redirect\" title=\"Anti-retroviral\">anti-retroviral</a></td>\n<td><a href=\"/wiki/HLA-C#Nomenclature\" title=\"HLA-C\">HLA-Cw*8</a> or <a href=\"/wiki/HLA-C#Nomenclature\" title=\"HLA-C\">HLA-Cw*8:-B*14</a></td>\n<td>DRESS syndrome</td>\n<td>18%</td>\n<td>96%</td>\n<td>Italian, Japanese\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Nevirapine\" title=\"Nevirapine\">Nevirapine</a></td>\n<td><a href=\"/wiki/Anti-retroviral\" class=\"mw-redirect\" title=\"Anti-retroviral\">anti-retroviral</a></td>\n<td><a href=\"/wiki/HLA-B35\" title=\"HLA-B35\">HLA-B*35</a>, <a href=\"/wiki/HLA-B35\" title=\"HLA-B35\">HLA-B*35:01</a>, or <a href=\"/wiki/HLA-B35\" title=\"HLA-B35\">HLA-B*35:05</a></td>\n<td>SJS, TEN, SJS/TEN</td>\n<td>?</td>\n<td>?</td>\n<td>Asian\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Nevirapine\" title=\"Nevirapine\">Nevirapine</a></td>\n<td><a href=\"/wiki/Anti-retroviral\" class=\"mw-redirect\" title=\"Anti-retroviral\">anti-retroviral</a></td>\n<td><a href=\"/wiki/HLA-C#Nomenclature\" title=\"HLA-C\">HLA-C*04:01</a></td>\n<td>SJS, TEN, SJS/TEN</td>\n<td>?</td>\n<td>?</td>\n<td><a href=\"/wiki/Malawian\" class=\"mw-redirect\" title=\"Malawian\">Malawian</a>\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Abacavir\" title=\"Abacavir\">Abacavir</a></td>\n<td><a href=\"/wiki/Anti-retroviral\" class=\"mw-redirect\" title=\"Anti-retroviral\">anti-retroviral</a></td>\n<td><a href=\"/wiki/HLA-B57#Serotype\" title=\"HLA-B57\">HLA-B*57:01</a></td>\n<td>DRESS syndrome</td>\n<td>55%</td>\n<td>100%</td>\n<td>European, African\n</td></tr>\n \n</tbody></table>\n<h3><span class=\"mw-headline\" id=\"T_cell_receptors\">T cell receptors</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Severe_cutaneous_adverse_reactions&amp;action=edit&amp;section=7\" title=\"Edit section: T cell receptors\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Due to gene editing. the number of diverse T cell receptors expressed is estimated to be as high as 10 trillion. This has made it difficult to identify specific T cell receptor types that are uniquely associated with the development of SCARs. One study, however, identified the preferential presence of the <a href=\"/wiki/V(D)J_recombination\" title=\"V(D)J recombination\">TCR-V-b</a> and <a href=\"/wiki/Complementarity_determining_region\" class=\"mw-redirect\" title=\"Complementarity determining region\">complementarity determining region</a> 3 in <a href=\"/wiki/T_cell_receptor#Structural_characteristics_of_the_TCR\" class=\"mw-redirect\" title=\"T cell receptor\">T cell receptors</a> found on the T cells in the blisters of patients with allopurinol-induced SCARs. This finding is compatible with the notion that specific types of T cell receptors are involved in the development of specific drug-induced SCARs.<sup id=\"cite_ref-pmid27362322_15-0\" class=\"reference\"><a href=\"#cite_note-pmid27362322-15\">&#91;15&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"ADME\">ADME</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Severe_cutaneous_adverse_reactions&amp;action=edit&amp;section=8\" title=\"Edit section: ADME\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Certain variations in <a href=\"/wiki/ADME\" title=\"ADME\">ADME</a> (i.e. <a href=\"/wiki/Absorption_(pharmacokinetics)\" class=\"mw-redirect\" title=\"Absorption (pharmacokinetics)\">absorption</a>, <a href=\"/wiki/Distribution_(pharmacology)\" title=\"Distribution (pharmacology)\">distribution</a>, <a href=\"/wiki/Metabolism\" title=\"Metabolism\">metabolism</a>, and <a href=\"/wiki/Excretion\" title=\"Excretion\">excretion</a> of a drug) are associated with the development of SCARs. These variations influence the levels and duration of a drug or drug metabolite in tissues and thereby impact the drug's or drug metabolite's ability to evoke SCARs.<sup id=\"cite_ref-pmid28256714_1-3\" class=\"reference\"><a href=\"#cite_note-pmid28256714-1\">&#91;1&#93;</a></sup> A prominent example of an ADME-based genetic predisposition to SCARs involves the CYP2CP*3 allele of the <a href=\"/wiki/CYP2C9\" title=\"CYP2C9\">CYP2C9</a> gene. CYP2C9, a <a href=\"/wiki/Cytochrome_P450\" title=\"Cytochrome P450\">cytochrome P450</a> enzyme, metabolizes various substances including phenytoin. The CYP2CP*3 variant of CYP29C has reduced catalytic activity. Individuals studied in Japan or Malaysia, and the Han Chinese in Taiwan that express this variant have an increased chance of developing the DRESS syndrome, SJS, SJS/TEN, or TEN when taking phenytoin while Africans in Mozambique expressing this variant taking phenytoin have an increase risk of developing SJS, SJS/TEN, or TEN. These reactions appear due to increases in the drug's blood and tissue levels.<sup id=\"cite_ref-pmid27154258_16-0\" class=\"reference\"><a href=\"#cite_note-pmid27154258-16\">&#91;16&#93;</a></sup> In a second example of a genetically based ADME  defect causing SCARs, Japanese individuals bearing slow acetylating variants of the <a href=\"/wiki/N-acetyltransferase_2\" title=\"N-acetyltransferase 2\">N-acetyltransferase 2</a> gene, (NAT2), viz., NAT2*6A and NAT2*7B, acetylate <a href=\"/wiki/Sulfasalazine\" title=\"Sulfasalazine\">sulfasalazine</a> more slowly than individuals homozygous for the wild type gene. Individuals expressing the NAT2*6A and NAT2*7 variants have an increased risk for developing a particularly severe form of the DRESS syndrome-like reactions to this <a href=\"/wiki/Anti-inflammatory_drug\" class=\"mw-redirect\" title=\"Anti-inflammatory drug\">anti-inflammatory drug</a>.<sup id=\"cite_ref-pmid28138822_10-1\" class=\"reference\"><a href=\"#cite_note-pmid28138822-10\">&#91;10&#93;</a></sup> None-genetic ADME factors are also associated with increased risks of developing SCARs. For example, allopurinol is metabolized to <a href=\"/wiki/Oxipurinol\" title=\"Oxipurinol\">oxipurinol</a>, a product with a far slower renal excretion rate than its parent compound. Renal impairment is associated with abnormally high blood levels of oxipurinol and an increased risk of developing the DRESS syndrome, particularly the more severe forms of this disorder. Dysfunction of the kidney and liver are also suggested to promote SCARs responses to other drugs due to the accumulation of SCARs-inducing drugs or metabolites in blood and tissues.<sup id=\"cite_ref-pmid28256714_1-4\" class=\"reference\"><a href=\"#cite_note-pmid28256714-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-pmid29188475_6-2\" class=\"reference\"><a href=\"#cite_note-pmid29188475-6\">&#91;6&#93;</a></sup> Currently, it is suspected that the expression of particular HLA proteins and T cell receptors interact with ADME factors to promote SCARs particularly in their more serious forms.<sup id=\"cite_ref-pmid28256714_1-5\" class=\"reference\"><a href=\"#cite_note-pmid28256714-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-pmid27154258_16-1\" class=\"reference\"><a href=\"#cite_note-pmid27154258-16\">&#91;16&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Other_factors\">Other factors</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Severe_cutaneous_adverse_reactions&amp;action=edit&amp;section=9\" title=\"Edit section: Other factors\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<h4><span class=\"mw-headline\" id=\"Virus_reactivation\">Virus reactivation</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Severe_cutaneous_adverse_reactions&amp;action=edit&amp;section=10\" title=\"Edit section: Virus reactivation\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\n<p>During the progression of the DRESS syndrome certain viruses which previously infected an individual and then became <a href=\"/wiki/Viral_latency\" class=\"mw-redirect\" title=\"Viral latency\">latent</a> are reactivated and proliferate. Viruses known to do so include certain members of the <a href=\"/wiki/Herpesviridae\" title=\"Herpesviridae\">Herpesviridae</a> family of Herpes viruses viz., <a href=\"/wiki/Epstein-Barr_virus\" class=\"mw-redirect\" title=\"Epstein-Barr virus\">Epstein-Barr virus</a>, <a href=\"/wiki/Human_herpesvirus_6\" title=\"Human herpesvirus 6\">human herpesvirus 6</a>, <a href=\"/wiki/Human_herpesvirus_7\" title=\"Human herpesvirus 7\">human herpesvirus 7</a>, and <a href=\"/wiki/Cytomegalovirus\" title=\"Cytomegalovirus\">cytomegalovirus</a>. Individuals suffering the DRESS syndrome may exhibit sequential reactivation of these four virus, typically in the order just given. Reactivation of these viruses is associated with sequential flare-ups in symptoms, a prolonged course, and increased disease severity which includes significant organ involvement and the development of certain <a href=\"/wiki/Autoimmune_disease\" title=\"Autoimmune disease\">autoimmune diseases</a> viz., <a href=\"/wiki/Systemic_lupus_erythematosus\" title=\"Systemic lupus erythematosus\">systemic lupus erythematosus</a>, <a href=\"/wiki/Autoimmune_thyroiditis\" title=\"Autoimmune thyroiditis\">autoimmune thyroiditis</a>, and <a href=\"/wiki/Type_1_diabetes_mellitus\" class=\"mw-redirect\" title=\"Type 1 diabetes mellitus\">type 1 diabetes mellitus</a>. While these viral reactivations, particularly of human herpes virus 6, have been suggested to be an important factor in the pathogenesis of the DRESS syndrome, studies to date have not clearly determined if they are a cause or merely a consequence of T cell-mediated tissue injury. Rare case reports have associated the SJS/TEN spectrum of SCARs with reactivation of human herpesvirus 6; reactivation of cytomegalovirus has also been proposed to be associated with AGEP although a large study failed to observe the latter association. In all cases, the relationships of viral reactivation to the development and severity of any SCARs disorder is uncertain and requires further study.<sup id=\"cite_ref-pmid28256714_1-6\" class=\"reference\"><a href=\"#cite_note-pmid28256714-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-pmid28598363_4-5\" class=\"reference\"><a href=\"#cite_note-pmid28598363-4\">&#91;4&#93;</a></sup>\n</p>\n<h4><span class=\"mw-headline\" id=\"Infections\">Infections</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Severe_cutaneous_adverse_reactions&amp;action=edit&amp;section=11\" title=\"Edit section: Infections\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\n<p>Although more than 90% of AGEP are associated with the intake of a presumptively offending drug, reports have associated infection with <a href=\"/wiki/Parvovirus_B19\" title=\"Parvovirus B19\">Parvovirus B19</a>, <a href=\"/wiki/Mycoplasma\" title=\"Mycoplasma\">mycoplasma</a>, <a href=\"/wiki/Cytomegalovirus\" title=\"Cytomegalovirus\">cytomegalovirus</a>, <a href=\"/wiki/Coxsackie_B4\" class=\"mw-redirect\" title=\"Coxsackie B4\">coxsackie B4</a> virus, <i><a href=\"/wiki/Chlamydophila_pneumoniae\" title=\"Chlamydophila pneumoniae\">Chlamydophila pneumoniae</a></i>, <i><a href=\"/wiki/E._Coli\" class=\"mw-redirect\" title=\"E. Coli\">E. Coli</a></i>, and <i><a href=\"/wiki/Echinococcus\" title=\"Echinococcus\">Echinococcus</a></i> with the drug-independent development of this disorder. The pathophysiology for the development of these drug-independent cases of AGEP is unclear.<sup id=\"cite_ref-pmid27472323_11-2\" class=\"reference\"><a href=\"#cite_note-pmid27472323-11\">&#91;11&#93;</a></sup> Viral infections have also been observed to be associated with the development of SJS, SJS/TEN, and TEN in the absence of a causative drug.<sup id=\"cite_ref-pmid29188475_6-3\" class=\"reference\"><a href=\"#cite_note-pmid29188475-6\">&#91;6&#93;</a></sup>\n</p>\n<h4><span class=\"mw-headline\" id=\"Autoimmune_Disorders\">Autoimmune Disorders</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Severe_cutaneous_adverse_reactions&amp;action=edit&amp;section=12\" title=\"Edit section: Autoimmune Disorders\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\n<p>Individuals suffering <a href=\"/wiki/Autoimmune_disorders\" class=\"mw-redirect\" title=\"Autoimmune disorders\">autoimmune disorders</a> such as <a href=\"/wiki/Systemic_lupus_erythematosus\" title=\"Systemic lupus erythematosus\">systemic lupus erythematosus</a> may have an increased incidence of developing SCARs. While the cause for this possible predilection has not been determined, the altered immune system and the excessive production of <a href=\"/wiki/Cytokine\" title=\"Cytokine\">cytokines</a> occurring in these disorders could be contributing factors.<sup id=\"cite_ref-pmid26553194_2-5\" class=\"reference\"><a href=\"#cite_note-pmid26553194-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-pmid29188475_6-4\" class=\"reference\"><a href=\"#cite_note-pmid29188475-6\">&#91;6&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Effectors_of_tissue_injury\">Effectors of tissue injury</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Severe_cutaneous_adverse_reactions&amp;action=edit&amp;section=13\" title=\"Edit section: Effectors of tissue injury\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>The tissue injury in SCARs is initiated principally by CD8<sup>+</sup> or CD4<sup>+</sup> T cells. Once drug-activated, these <a href=\"/wiki/Lymphocytes\" class=\"mw-redirect\" title=\"Lymphocytes\">lymphocytes</a> elicit immune responses to self tissues that can result in SCARs drug reactions by mechanisms which vary with the type of disorder that develops. Salient elements mediating tissue injury for each type of disorder include:<sup id=\"cite_ref-pmid26553194_2-6\" class=\"reference\"><a href=\"#cite_note-pmid26553194-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-pmid28476287_13-4\" class=\"reference\"><a href=\"#cite_note-pmid28476287-13\">&#91;13&#93;</a></sup>\n</p>\n<ul><li>SJS, SJS/TEN, and TEN: These three SCARs are variants of a common epidermal necrolysis disorder that differ only in severity. Key down-stream elements that promote tissue injury in this spectrum of disorders are <a href=\"/wiki/Natural_killer_cells\" class=\"mw-redirect\" title=\"Natural killer cells\">natural killer cells</a>; death-inducing ligands that kill cells (viz., <a href=\"/wiki/Fas_ligand\" title=\"Fas ligand\">Fas ligand</a>, <a href=\"/wiki/TRAIL\" title=\"TRAIL\">TRAIL</a>, and <a href=\"/wiki/TNFSF12\" title=\"TNFSF12\">TNFSF12</a>); cellular receptors for these ligands (viz., <a href=\"/wiki/Fas_receptor\" title=\"Fas receptor\">Fas receptor</a>, <a href=\"/wiki/Death_receptor_4\" title=\"Death receptor 4\">death receptor 4</a>, <a href=\"/wiki/Death_receptor_5\" title=\"Death receptor 5\">death receptor 5</a>, and <a href=\"/wiki/TNFRSF12A\" title=\"TNFRSF12A\">TNFRSF12A</a>); cell-injuring proteins made by CD8<sup>+</sup> and natural killer cells, (viz., <a href=\"/wiki/Granulysin\" title=\"Granulysin\">granulysin</a>, <a href=\"/wiki/Granzyme_B\" title=\"Granzyme B\">granzyme B</a>, and <a href=\"/wiki/Perforin\" title=\"Perforin\">perforin</a>); and two cytokines that stimulate the proliferation and activation of natural killer and T cells (viz., <a href=\"/wiki/Interleukin_5\" title=\"Interleukin 5\">interleukin 5</a> and <a href=\"/wiki/Annexin_A1\" title=\"Annexin A1\">annexin A1</a>).</li>\n<li>DRESS syndrome: Key elements promoting tissue injury in the DRESS syndrome are: <a href=\"/wiki/Th2_cells\" class=\"mw-redirect\" title=\"Th2 cells\">Th2 cells</a> and <a href=\"/wiki/Eosinophils\" class=\"mw-redirect\" title=\"Eosinophils\">eosinophils</a>; and <a href=\"/wiki/Cytokines\" class=\"mw-redirect\" title=\"Cytokines\">cytokiness</a> which either activate eosinophils (viz.,. <a href=\"/wiki/Interleukin_5\" title=\"Interleukin 5\">Interleukin 5</a>), promote adaptive and allergic immune responses (viz., <a href=\"/wiki/Interleukin_4\" title=\"Interleukin 4\">Interleukin 4</a>), promote allergic responses and tissue <a href=\"/wiki/Fibrosis\" title=\"Fibrosis\">fibrosis</a> (viz., <a href=\"/wiki/Interleukin_13\" title=\"Interleukin 13\">Interleukin 13</a>), promote innate, adaptive, and auto-immune responses (viz., <a href=\"/wiki/Interferon_gamma\" title=\"Interferon gamma\">interferon gamma</a>); or cause cell death (viz., <a href=\"/wiki/Tumor_necrosis_factor_alpha\" title=\"Tumor necrosis factor alpha\">tumor necrosis factor alpha</a>).</li>\n<li>AGEP: Key elements promoting tissue injury in AGEP are: <a href=\"/wiki/Neutrophils\" class=\"mw-redirect\" title=\"Neutrophils\">neutrophils</a>; recruiters and activators of neutrophils (viz., <a href=\"/wiki/Interleukin_8\" title=\"Interleukin 8\">Interleukin 8</a> and <a href=\"/wiki/Interleukin_17\" title=\"Interleukin 17\">Interleukin 17</a>); a promoter of innate immune and autoimmune responses (viz., <a href=\"/wiki/Interleukin_22\" title=\"Interleukin 22\">Interleukin 22</a>); and a cytokine which promotes the function of neutrophils, other <a href=\"/wiki/Granulocyte\" title=\"Granulocyte\">granulocyte</a> types, and monocytes as well as the production of these cells from their <a href=\"/wiki/Stem_cells\" class=\"mw-redirect\" title=\"Stem cells\">stem cells</a> (viz., <a href=\"/wiki/GM-CSF\" class=\"mw-redirect\" title=\"GM-CSF\">GM-CSF</a>).</li></ul>\n<p>Future studies may find that drugs which neutralize one or more of these effectors to be useful for treating SCARs disorders.\n</p>\n<h2><span class=\"mw-headline\" id=\"Prevention\">Prevention</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Severe_cutaneous_adverse_reactions&amp;action=edit&amp;section=14\" title=\"Edit section: Prevention\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Screening individuals for the expression of certain variant <a href=\"/wiki/Alleles\" class=\"mw-redirect\" title=\"Alleles\">alleles</a> of HLA genes before initiating treatment with particular SCARs-inducing drugs is recommended. These recommendations typically apply only to specific populations that have a significant chance of expressing the indicated variant since screening of populations with extremely low incidences of expressing the variant allele is considered cost-ineffective.<sup id=\"cite_ref-pmid28346659_17-0\" class=\"reference\"><a href=\"#cite_note-pmid28346659-17\">&#91;17&#93;</a></sup> Individuals expressing the HLA allele associated with sensitivity to an indicated drug should not be treated with the drug. These recommendations include:<sup id=\"cite_ref-pmid28256714_1-7\" class=\"reference\"><a href=\"#cite_note-pmid28256714-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-pmid27854302_18-0\" class=\"reference\"><a href=\"#cite_note-pmid27854302-18\">&#91;18&#93;</a></sup>\n</p>\n<ul><li>Carbamazepine: The Taiwan and USA Food and Drug Administrations recommend screening for HLA-B*15:02 in certain Asian groups before carbamazepine treatment. This has been implemented in Taiwan, Hong Kong, Singapore, and many medical centers in Thailand and Mainland China.</li>\n<li>Allopurinol: The American College of Rheumatology guidelines for the management of gout recommend HLA-B*58:01 screening before allopurinol treatment. This is provided in many medical centers in Taiwan, Hong Kong, Thailand, and Mainland China.</li>\n<li>Abacavir: The USA Food and Drug Administration recommends screening for HLA-B*57:01 in the treatment of <a href=\"/wiki/HIV\" title=\"HIV\">HIV</a> with abacovir in Caucasian populations. This screening is widely implemented. It has also been suggested that all individuals found to express this HLA serotype avoid treatment with abacovir.</li></ul>\n<p>Current trials are underway to evaluate the cost-effectiveness of genetic screening for HLA-B*13:01 to prevent dapsone-induced SCARs in China and Indonesia. Similar trials are underway in Taiwan to prevent phenytoin-induced SCARs in individuals expressing the CYP2C9*3 allele of CYP2C9 or a series of HLA alleles.<sup id=\"cite_ref-pmid27854302_18-1\" class=\"reference\"><a href=\"#cite_note-pmid27854302-18\">&#91;18&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Severe_cutaneous_adverse_reactions&amp;action=edit&amp;section=15\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist\" style=\"list-style-type: decimal;\">\n<div class=\"mw-references-wrap mw-references-columns\"><ol class=\"references\">\n<li id=\"cite_note-pmid28256714-1\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid28256714_1-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid28256714_1-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-pmid28256714_1-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-pmid28256714_1-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-pmid28256714_1-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-pmid28256714_1-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-pmid28256714_1-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-pmid28256714_1-7\"><sup><i><b>h</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Adler NR, Aung AK, Ergen EN, Trubiano J, Goh MS, Phillips EJ (2017). \"Recent advances in the understanding of severe cutaneous adverse reactions\". <i>The British Journal of Dermatology</i>. <b>177</b> (5): 1234\u20131247. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1111/bjd.15423\">10.1111/bjd.15423</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/28256714\">28256714</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+British+Journal+of+Dermatology&amp;rft.atitle=Recent+advances+in+the+understanding+of+severe+cutaneous+adverse+reactions&amp;rft.volume=177&amp;rft.issue=5&amp;rft.pages=1234-1247&amp;rft.date=2017&amp;rft_id=info%3Adoi%2F10.1111%2Fbjd.15423&amp;rft_id=info%3Apmid%2F28256714&amp;rft.aulast=Adler&amp;rft.aufirst=NR&amp;rft.au=Aung%2C+AK&amp;rft.au=Ergen%2C+EN&amp;rft.au=Trubiano%2C+J&amp;rft.au=Goh%2C+MS&amp;rft.au=Phillips%2C+EJ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ASevere+cutaneous+adverse+reactions\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid26553194-2\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid26553194_2-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid26553194_2-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-pmid26553194_2-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-pmid26553194_2-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-pmid26553194_2-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-pmid26553194_2-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-pmid26553194_2-6\"><sup><i><b>g</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Hoetzenecker W, N\u00e4geli M, Mehra ET, Jensen AN, Saulite I, Schmid-Grendelmeier P, Guenova E, Cozzio A, French LE (2016). \"Adverse cutaneous drug eruptions: current understanding\". <i>Seminars in Immunopathology</i>. <b>38</b> (1): 75\u201386. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1007/s00281-015-0540-2\">10.1007/s00281-015-0540-2</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/26553194\">26553194</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Seminars+in+Immunopathology&amp;rft.atitle=Adverse+cutaneous+drug+eruptions%3A+current+understanding&amp;rft.volume=38&amp;rft.issue=1&amp;rft.pages=75-86&amp;rft.date=2016&amp;rft_id=info%3Adoi%2F10.1007%2Fs00281-015-0540-2&amp;rft_id=info%3Apmid%2F26553194&amp;rft.aulast=Hoetzenecker&amp;rft.aufirst=W&amp;rft.au=N%C3%A4geli%2C+M&amp;rft.au=Mehra%2C+ET&amp;rft.au=Jensen%2C+AN&amp;rft.au=Saulite%2C+I&amp;rft.au=Schmid-Grendelmeier%2C+P&amp;rft.au=Guenova%2C+E&amp;rft.au=Cozzio%2C+A&amp;rft.au=French%2C+LE&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ASevere+cutaneous+adverse+reactions\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid28345177-3\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid28345177_3-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid28345177_3-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-pmid28345177_3-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-pmid28345177_3-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-pmid28345177_3-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-pmid28345177_3-5\"><sup><i><b>f</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Garon SL, Pavlos RK, White KD, Brown NJ, Stone CA, Phillips EJ (2017). \"Pharmacogenomics of off-target adverse drug reactions\". <i>British Journal of Clinical Pharmacology</i>. <b>83</b> (9): 1896\u20131911. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1111/bcp.13294\">10.1111/bcp.13294</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/28345177\">28345177</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=British+Journal+of+Clinical+Pharmacology&amp;rft.atitle=Pharmacogenomics+of+off-target+adverse+drug+reactions&amp;rft.volume=83&amp;rft.issue=9&amp;rft.pages=1896-1911&amp;rft.date=2017&amp;rft_id=info%3Adoi%2F10.1111%2Fbcp.13294&amp;rft_id=info%3Apmid%2F28345177&amp;rft.aulast=Garon&amp;rft.aufirst=SL&amp;rft.au=Pavlos%2C+RK&amp;rft.au=White%2C+KD&amp;rft.au=Brown%2C+NJ&amp;rft.au=Stone%2C+CA&amp;rft.au=Phillips%2C+EJ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ASevere+cutaneous+adverse+reactions\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid28598363-4\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid28598363_4-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid28598363_4-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-pmid28598363_4-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-pmid28598363_4-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-pmid28598363_4-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-pmid28598363_4-5\"><sup><i><b>f</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Cho YT, Yang CW, Chu CY (2017). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5486066\">\"Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Interplay among Drugs, Viruses, and Immune System\"</a>. <i>International Journal of Molecular Sciences</i>. <b>18</b> (6). <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.3390/ijms18061243\">10.3390/ijms18061243</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5486066\">5486066</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/28598363\">28598363</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=International+Journal+of+Molecular+Sciences&amp;rft.atitle=Drug+Reaction+with+Eosinophilia+and+Systemic+Symptoms+%28DRESS%29%3A+An+Interplay+among+Drugs%2C+Viruses%2C+and+Immune+System&amp;rft.volume=18&amp;rft.issue=6&amp;rft.date=2017&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5486066&amp;rft_id=info%3Apmid%2F28598363&amp;rft_id=info%3Adoi%2F10.3390%2Fijms18061243&amp;rft.aulast=Cho&amp;rft.aufirst=YT&amp;rft.au=Yang%2C+CW&amp;rft.au=Chu%2C+CY&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5486066&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ASevere+cutaneous+adverse+reactions\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid27960170-5\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid27960170_5-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid27960170_5-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Pichler WJ, Hausmann O (2016). \"Classification of Drug Hypersensitivity into Allergic, p-i, and Pseudo-Allergic Forms\". <i>International Archives of Allergy and Immunology</i>. <b>171</b> (3-4): 166\u2013179. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1159/000453265\">10.1159/000453265</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/27960170\">27960170</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=International+Archives+of+Allergy+and+Immunology&amp;rft.atitle=Classification+of+Drug+Hypersensitivity+into+Allergic%2C+p-i%2C+and+Pseudo-Allergic+Forms&amp;rft.volume=171&amp;rft.issue=3-4&amp;rft.pages=166-179&amp;rft.date=2016&amp;rft_id=info%3Adoi%2F10.1159%2F000453265&amp;rft_id=info%3Apmid%2F27960170&amp;rft.aulast=Pichler&amp;rft.aufirst=WJ&amp;rft.au=Hausmann%2C+O&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ASevere+cutaneous+adverse+reactions\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid29188475-6\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid29188475_6-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid29188475_6-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-pmid29188475_6-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-pmid29188475_6-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-pmid29188475_6-4\"><sup><i><b>e</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T (2017). \"Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis\". <i>Clinical Reviews in Allergy &amp; Immunology</i>. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1007/s12016-017-8654-z\">10.1007/s12016-017-8654-z</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/29188475\">29188475</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+Reviews+in+Allergy+%26+Immunology&amp;rft.atitle=Current+Perspectives+on+Stevens-Johnson+Syndrome+and+Toxic+Epidermal+Necrolysis&amp;rft.date=2017&amp;rft_id=info%3Adoi%2F10.1007%2Fs12016-017-8654-z&amp;rft_id=info%3Apmid%2F29188475&amp;rft.aulast=Lerch&amp;rft.aufirst=M&amp;rft.au=Mainetti%2C+C&amp;rft.au=Terziroli+Beretta-Piccoli%2C+B&amp;rft.au=Harr%2C+T&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ASevere+cutaneous+adverse+reactions\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid28439852-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid28439852_7-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Schneider JA, Cohen PR (2017). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5487863\">\"Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures\"</a>. <i>Advances in Therapy</i>. <b>34</b> (6): 1235\u20131244. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1007/s12325-017-0530-y\">10.1007/s12325-017-0530-y</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5487863\">5487863</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/28439852\">28439852</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Advances+in+Therapy&amp;rft.atitle=Stevens-Johnson+Syndrome+and+Toxic+Epidermal+Necrolysis%3A+A+Concise+Review+with+a+Comprehensive+Summary+of+Therapeutic+Interventions+Emphasizing+Supportive+Measures&amp;rft.volume=34&amp;rft.issue=6&amp;rft.pages=1235-1244&amp;rft.date=2017&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5487863&amp;rft_id=info%3Apmid%2F28439852&amp;rft_id=info%3Adoi%2F10.1007%2Fs12325-017-0530-y&amp;rft.aulast=Schneider&amp;rft.aufirst=JA&amp;rft.au=Cohen%2C+PR&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5487863&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ASevere+cutaneous+adverse+reactions\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid22794701-8\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid22794701_8-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Uzzaman A, Cho SH (2012). \"Chapter 28: Classification of hypersensitivity reactions\". <i>Allergy and Asthma Proceedings</i>. 33 Suppl 1: S96\u20139. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.2500/aap.2012.33.3561\">10.2500/aap.2012.33.3561</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/22794701\">22794701</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Allergy+and+Asthma+Proceedings&amp;rft.atitle=Chapter+28%3A+Classification+of+hypersensitivity+reactions&amp;rft.volume=33+Suppl+1&amp;rft.pages=S96-9&amp;rft.date=2012&amp;rft_id=info%3Adoi%2F10.2500%2Faap.2012.33.3561&amp;rft_id=info%3Apmid%2F22794701&amp;rft.aulast=Uzzaman&amp;rft.aufirst=A&amp;rft.au=Cho%2C+SH&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ASevere+cutaneous+adverse+reactions\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid28665896-9\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid28665896_9-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Corneli HM (2017). \"DRESS Syndrome: Drug Reaction With Eosinophilia and Systemic Symptoms\". <i>Pediatric Emergency Care</i>. <b>33</b> (7): 499\u2013502. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1097/PEC.0000000000001188\">10.1097/PEC.0000000000001188</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/28665896\">28665896</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Pediatric+Emergency+Care&amp;rft.atitle=DRESS+Syndrome%3A+Drug+Reaction+With+Eosinophilia+and+Systemic+Symptoms&amp;rft.volume=33&amp;rft.issue=7&amp;rft.pages=499-502&amp;rft.date=2017&amp;rft_id=info%3Adoi%2F10.1097%2FPEC.0000000000001188&amp;rft_id=info%3Apmid%2F28665896&amp;rft.aulast=Corneli&amp;rft.aufirst=HM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ASevere+cutaneous+adverse+reactions\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid28138822-10\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid28138822_10-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid28138822_10-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Adwan MH (2017). \"Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome and the Rheumatologist\". <i>Current Rheumatology Reports</i>. <b>19</b> (1): 3. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1007/s11926-017-0626-z\">10.1007/s11926-017-0626-z</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/28138822\">28138822</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Current+Rheumatology+Reports&amp;rft.atitle=Drug+Reaction+with+Eosinophilia+and+Systemic+Symptoms+%28DRESS%29+Syndrome+and+the+Rheumatologist&amp;rft.volume=19&amp;rft.issue=1&amp;rft.pages=3&amp;rft.date=2017&amp;rft_id=info%3Adoi%2F10.1007%2Fs11926-017-0626-z&amp;rft_id=info%3Apmid%2F28138822&amp;rft.aulast=Adwan&amp;rft.aufirst=MH&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ASevere+cutaneous+adverse+reactions\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid27472323-11\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid27472323_11-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid27472323_11-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-pmid27472323_11-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Feldmeyer L, Heidemeyer K, Yawalkar N (2016). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5000612\">\"Acute Generalized Exanthematous Pustulosis: Pathogenesis, Genetic Background, Clinical Variants and Therapy\"</a>. <i>International Journal of Molecular Sciences</i>. <b>17</b> (8). <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.3390/ijms17081214\">10.3390/ijms17081214</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5000612\">5000612</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/27472323\">27472323</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=International+Journal+of+Molecular+Sciences&amp;rft.atitle=Acute+Generalized+Exanthematous+Pustulosis%3A+Pathogenesis%2C+Genetic+Background%2C+Clinical+Variants+and+Therapy&amp;rft.volume=17&amp;rft.issue=8&amp;rft.date=2016&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5000612&amp;rft_id=info%3Apmid%2F27472323&amp;rft_id=info%3Adoi%2F10.3390%2Fijms17081214&amp;rft.aulast=Feldmeyer&amp;rft.aufirst=L&amp;rft.au=Heidemeyer%2C+K&amp;rft.au=Yawalkar%2C+N&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5000612&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ASevere+cutaneous+adverse+reactions\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid28084022-12\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid28084022_12-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Alniemi DT, Wetter DA, Bridges AG, El-Azhary RA, Davis MD, Camilleri MJ, McEvoy MT (2017). \"Acute generalized exanthematous pustulosis: clinical characteristics, etiologic associations, treatments, and outcomes in a series of 28 patients at Mayo Clinic, 1996-2013\". <i>International Journal of Dermatology</i>. <b>56</b> (4): 405\u2013414. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1111/ijd.13434\">10.1111/ijd.13434</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/28084022\">28084022</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=International+Journal+of+Dermatology&amp;rft.atitle=Acute+generalized+exanthematous+pustulosis%3A+clinical+characteristics%2C+etiologic+associations%2C+treatments%2C+and+outcomes+in+a+series+of+28+patients+at+Mayo+Clinic%2C+1996-2013&amp;rft.volume=56&amp;rft.issue=4&amp;rft.pages=405-414&amp;rft.date=2017&amp;rft_id=info%3Adoi%2F10.1111%2Fijd.13434&amp;rft_id=info%3Apmid%2F28084022&amp;rft.aulast=Alniemi&amp;rft.aufirst=DT&amp;rft.au=Wetter%2C+DA&amp;rft.au=Bridges%2C+AG&amp;rft.au=El-Azhary%2C+RA&amp;rft.au=Davis%2C+MD&amp;rft.au=Camilleri%2C+MJ&amp;rft.au=McEvoy%2C+MT&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ASevere+cutaneous+adverse+reactions\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid28476287-13\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid28476287_13-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid28476287_13-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-pmid28476287_13-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-pmid28476287_13-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-pmid28476287_13-4\"><sup><i><b>e</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O (2017). \"Severe cutaneous adverse reactions to drugs\". <i>Lancet</i>. <b>390</b> (10106): 1996\u20132011. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/S0140-6736%2816%2930378-6\">10.1016/S0140-6736(16)30378-6</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/28476287\">28476287</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Lancet&amp;rft.atitle=Severe+cutaneous+adverse+reactions+to+drugs&amp;rft.volume=390&amp;rft.issue=10106&amp;rft.pages=1996-2011&amp;rft.date=2017&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2816%2930378-6&amp;rft_id=info%3Apmid%2F28476287&amp;rft.aulast=Duong&amp;rft.aufirst=TA&amp;rft.au=Valeyrie-Allanore%2C+L&amp;rft.au=Wolkenstein%2C+P&amp;rft.au=Chosidow%2C+O&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ASevere+cutaneous+adverse+reactions\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid29333460-14\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid29333460_14-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Fan WL, Shiao MS, Hui RC, Su SC, Wang CW, Chang YC, Chung WH (2017). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5733150\">\"HLA Association with Drug-Induced Adverse Reactions\"</a>. <i>Journal of Immunology Research</i>. <b>2017</b>: 3186328. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1155/2017/3186328\">10.1155/2017/3186328</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5733150\">5733150</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/29333460\">29333460</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Immunology+Research&amp;rft.atitle=HLA+Association+with+Drug-Induced+Adverse+Reactions&amp;rft.volume=2017&amp;rft.pages=3186328&amp;rft.date=2017&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5733150&amp;rft_id=info%3Apmid%2F29333460&amp;rft_id=info%3Adoi%2F10.1155%2F2017%2F3186328&amp;rft.aulast=Fan&amp;rft.aufirst=WL&amp;rft.au=Shiao%2C+MS&amp;rft.au=Hui%2C+RC&amp;rft.au=Su%2C+SC&amp;rft.au=Wang%2C+CW&amp;rft.au=Chang%2C+YC&amp;rft.au=Chung%2C+WH&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5733150&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ASevere+cutaneous+adverse+reactions\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid27362322-15\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid27362322_15-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Wang CW, Dao RL, Chung WH (2016). \"Immunopathogenesis and risk factors for allopurinol severe cutaneous adverse reactions\". <i>Current Opinion in Allergy and Clinical Immunology</i>. <b>16</b> (4): 339\u201345. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1097/ACI.0000000000000286\">10.1097/ACI.0000000000000286</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/27362322\">27362322</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Current+Opinion+in+Allergy+and+Clinical+Immunology&amp;rft.atitle=Immunopathogenesis+and+risk+factors+for+allopurinol+severe+cutaneous+adverse+reactions&amp;rft.volume=16&amp;rft.issue=4&amp;rft.pages=339-45&amp;rft.date=2016&amp;rft_id=info%3Adoi%2F10.1097%2FACI.0000000000000286&amp;rft_id=info%3Apmid%2F27362322&amp;rft.aulast=Wang&amp;rft.aufirst=CW&amp;rft.au=Dao%2C+RL&amp;rft.au=Chung%2C+WH&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ASevere+cutaneous+adverse+reactions\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid27154258-16\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid27154258_16-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid27154258_16-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Chung WH, Wang CW, Dao RL (July 2016). \"Severe cutaneous adverse drug reactions\". <i>The Journal of Dermatology</i>. <b>43</b> (7): 758\u201366. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1111/1346-8138.13430\">10.1111/1346-8138.13430</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/27154258\">27154258</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Journal+of+Dermatology&amp;rft.atitle=Severe+cutaneous+adverse+drug+reactions&amp;rft.volume=43&amp;rft.issue=7&amp;rft.pages=758-66&amp;rft.date=2016-07&amp;rft_id=info%3Adoi%2F10.1111%2F1346-8138.13430&amp;rft_id=info%3Apmid%2F27154258&amp;rft.aulast=Chung&amp;rft.aufirst=WH&amp;rft.au=Wang%2C+CW&amp;rft.au=Dao%2C+RL&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ASevere+cutaneous+adverse+reactions\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid28346659-17\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-pmid28346659_17-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Chong HY, Mohamed Z, Tan LL, Wu DB, Shabaruddin FH, Dahlui M, Apalasamy YD, Snyder SR, Williams MS, Hao J, Cavallari LH, Chaiyakunapruk N (2017). \"Is universal HLA-B*15:02 screening a cost-effective option in an ethnically diverse population? A case study of Malaysia\". <i>The British Journal of Dermatology</i>. <b>177</b> (4): 1102\u20131112. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1111/bjd.15498\">10.1111/bjd.15498</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/28346659\">28346659</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+British+Journal+of+Dermatology&amp;rft.atitle=Is+universal+HLA-B%2A15%3A02+screening+a+cost-effective+option+in+an+ethnically+diverse+population%3F+A+case+study+of+Malaysia&amp;rft.volume=177&amp;rft.issue=4&amp;rft.pages=1102-1112&amp;rft.date=2017&amp;rft_id=info%3Adoi%2F10.1111%2Fbjd.15498&amp;rft_id=info%3Apmid%2F28346659&amp;rft.aulast=Chong&amp;rft.aufirst=HY&amp;rft.au=Mohamed%2C+Z&amp;rft.au=Tan%2C+LL&amp;rft.au=Wu%2C+DB&amp;rft.au=Shabaruddin%2C+FH&amp;rft.au=Dahlui%2C+M&amp;rft.au=Apalasamy%2C+YD&amp;rft.au=Snyder%2C+SR&amp;rft.au=Williams%2C+MS&amp;rft.au=Hao%2C+J&amp;rft.au=Cavallari%2C+LH&amp;rft.au=Chaiyakunapruk%2C+N&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ASevere+cutaneous+adverse+reactions\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-pmid27854302-18\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-pmid27854302_18-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-pmid27854302_18-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Su SC, Hung SI, Fan WL, Dao RL, Chung WH (2016). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5133889\">\"Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation\"</a>. <i>International Journal of Molecular Sciences</i>. <b>17</b> (11). <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.3390/ijms17111890\">10.3390/ijms17111890</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC5133889\">5133889</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/27854302\">27854302</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=International+Journal+of+Molecular+Sciences&amp;rft.atitle=Severe+Cutaneous+Adverse+Reactions%3A+The+Pharmacogenomics+from+Research+to+Clinical+Implementation&amp;rft.volume=17&amp;rft.issue=11&amp;rft.date=2016&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5133889&amp;rft_id=info%3Apmid%2F27854302&amp;rft_id=info%3Adoi%2F10.3390%2Fijms17111890&amp;rft.aulast=Su&amp;rft.aufirst=SC&amp;rft.au=Hung%2C+SI&amp;rft.au=Fan%2C+WL&amp;rft.au=Dao%2C+RL&amp;rft.au=Chung%2C+WH&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5133889&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ASevere+cutaneous+adverse+reactions\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</ol></div></div>\n\n<!-- \nNewPP limit report\nParsed by mw2254\nCached time: 20180918224935\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.304 seconds\nReal time usage: 0.367 seconds\nPreprocessor visited node count: 1620/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 43582/2097152 bytes\nTemplate argument size: 286/2097152 bytes\nHighest expansion depth: 7/40\nExpensive parser function count: 0/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 37346/5000000 bytes\nNumber of Wikibase entities loaded: 1/400\nLua time usage: 0.139/10.000 seconds\nLua memory usage: 5.05 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  275.666      1 -total\n 54.81%  151.081      1 Template:Reflist\n 43.50%  119.928     18 Template:Cite_journal\n 30.63%   84.444      1 Template:Infobox_medical_condition_(new)\n 26.96%   74.306      1 Template:Infobox\n  4.75%   13.108      4 Template:Main_article\n  1.09%    3.004      1 Template:Template_other\n  1.01%    2.794      3 Template:Main_other\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:55941104-0!canonical and timestamp 20180918224934 and revision id 857229643\n -->\n</div>"},"langlinks":[],"categories":[{"sortkey":"","hidden":"","*":"Articles_which_use_infobox_templates_with_no_data_rows"},{"sortkey":"","hidden":"","*":"Infobox_medical_condition_(new)"},{"sortkey":"","*":"Drug_eruptions"},{"sortkey":"","*":"Syndromes"},{"sortkey":"","*":"Medication_side_effects"}],"links":[{"ns":0,"exists":"","*":"ADME"},{"ns":0,"exists":"","*":"Abacavir"},{"ns":0,"exists":"","*":"Absorption (pharmacokinetics)"},{"ns":0,"exists":"","*":"Acute generalized exanthematous pustulosis"},{"ns":0,"exists":"","*":"Adaptive immune system"},{"ns":0,"exists":"","*":"Adverse drug reaction"},{"ns":0,"exists":"","*":"Alleles"},{"ns":0,"exists":"","*":"Allopurinol"},{"ns":0,"exists":"","*":"Annexin A1"},{"ns":0,"exists":"","*":"Anti-inflammatory"},{"ns":0,"exists":"","*":"Anti-inflammatory drug"},{"ns":0,"exists":"","*":"Anti-retroviral"},{"ns":0,"exists":"","*":"Antibiotic"},{"ns":0,"exists":"","*":"Anticonvulsant"},{"ns":0,"exists":"","*":"Antigen-presenting cells"},{"ns":0,"exists":"","*":"Antigen presentation"},{"ns":0,"exists":"","*":"Antigens"},{"ns":0,"exists":"","*":"Asthma"},{"ns":0,"exists":"","*":"Autoimmune disease"},{"ns":0,"exists":"","*":"Autoimmune disorders"},{"ns":0,"exists":"","*":"Autoimmune thyroiditis"},{"ns":0,"exists":"","*":"B cells"},{"ns":0,"exists":"","*":"Basophils"},{"ns":0,"exists":"","*":"Biological"},{"ns":0,"exists":"","*":"Blister"},{"ns":0,"exists":"","*":"Body orifice"},{"ns":0,"exists":"","*":"CYP2C9"},{"ns":0,"exists":"","*":"Carbamazepine"},{"ns":0,"exists":"","*":"Celecoxib"},{"ns":0,"exists":"","*":"Chlamydophila pneumoniae"},{"ns":0,"exists":"","*":"Chlormezanone"},{"ns":0,"exists":"","*":"Complementarity determining region"},{"ns":0,"exists":"","*":"Covalent bond"},{"ns":0,"exists":"","*":"Coxsackie B4"},{"ns":0,"exists":"","*":"Cutaneous condition"},{"ns":0,"exists":"","*":"Cytochrome P450"},{"ns":0,"exists":"","*":"Cytokine"},{"ns":0,"exists":"","*":"Cytokines"},{"ns":0,"exists":"","*":"Cytomegalovirus"},{"ns":0,"exists":"","*":"Cytotoxic T cells"},{"ns":0,"exists":"","*":"DRESS syndrome"},{"ns":0,"exists":"","*":"Dapsone"},{"ns":0,"exists":"","*":"Death receptor 4"},{"ns":0,"exists":"","*":"Death receptor 5"},{"ns":0,"exists":"","*":"Delayed type hypersensitivity"},{"ns":0,"exists":"","*":"Dendritic cells"},{"ns":0,"exists":"","*":"Denudation"},{"ns":0,"exists":"","*":"Diclofenac"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"Distribution (pharmacology)"},{"ns":0,"exists":"","*":"Drug eruption"},{"ns":0,"exists":"","*":"Drug reaction with eosinophilia and systemic symptoms"},{"ns":0,"exists":"","*":"E. Coli"},{"ns":0,"exists":"","*":"Ear"},{"ns":0,"exists":"","*":"Echinococcus"},{"ns":0,"exists":"","*":"Edema"},{"ns":0,"exists":"","*":"Eosinophils"},{"ns":0,"exists":"","*":"Epitopes"},{"ns":0,"exists":"","*":"Epstein-Barr virus"},{"ns":0,"exists":"","*":"Erythematous"},{"ns":0,"exists":"","*":"Excretion"},{"ns":0,"exists":"","*":"Eye"},{"ns":0,"exists":"","*":"Fas ligand"},{"ns":0,"exists":"","*":"Fas receptor"},{"ns":0,"exists":"","*":"Fibrosis"},{"ns":0,"exists":"","*":"GM-CSF"},{"ns":0,"exists":"","*":"Genome editing"},{"ns":0,"exists":"","*":"Gout"},{"ns":0,"exists":"","*":"Granulocyte"},{"ns":0,"exists":"","*":"Granulysin"},{"ns":0,"exists":"","*":"Granzyme B"},{"ns":0,"exists":"","*":"HIV"},{"ns":0,"exists":"","*":"HLA-A"},{"ns":0,"exists":"","*":"HLA-A2"},{"ns":0,"exists":"","*":"HLA-A31"},{"ns":0,"exists":"","*":"HLA-A68"},{"ns":0,"exists":"","*":"HLA-B"},{"ns":0,"exists":"","*":"HLA-B12"},{"ns":0,"exists":"","*":"HLA-B13"},{"ns":0,"exists":"","*":"HLA-B15"},{"ns":0,"exists":"","*":"HLA-B35"},{"ns":0,"exists":"","*":"HLA-B38"},{"ns":0,"exists":"","*":"HLA-B57"},{"ns":0,"exists":"","*":"HLA-B58"},{"ns":0,"exists":"","*":"HLA-B59"},{"ns":0,"exists":"","*":"HLA-B73"},{"ns":0,"exists":"","*":"HLA-C"},{"ns":0,"exists":"","*":"HLA-Cw4"},{"ns":0,"exists":"","*":"HLA-DM"},{"ns":0,"exists":"","*":"HLA-DO"},{"ns":0,"exists":"","*":"HLA-DP"},{"ns":0,"exists":"","*":"HLA-DQ"},{"ns":0,"exists":"","*":"HLA-DQB1"},{"ns":0,"exists":"","*":"HLA-DR"},{"ns":0,"exists":"","*":"HLA-DRB1"},{"ns":0,"exists":"","*":"Han Chinese"},{"ns":0,"exists":"","*":"Hapten"},{"ns":0,"exists":"","*":"Helper T cell"},{"ns":0,"exists":"","*":"Herbalism"},{"ns":0,"exists":"","*":"Herpesviridae"},{"ns":0,"exists":"","*":"Histamine"},{"ns":0,"exists":"","*":"Human herpesvirus 6"},{"ns":0,"exists":"","*":"Human herpesvirus 7"},{"ns":0,"exists":"","*":"Human leukocyte antigen"},{"ns":0,"exists":"","*":"Hypereosinophilia"},{"ns":0,"exists":"","*":"Ibuprofen"},{"ns":0,"exists":"","*":"IgE"},{"ns":0,"exists":"","*":"IgG"},{"ns":0,"exists":"","*":"IgM"},{"ns":0,"exists":"","*":"Innate immune system"},{"ns":0,"exists":"","*":"Interferon gamma"},{"ns":0,"exists":"","*":"Interleukin 13"},{"ns":0,"exists":"","*":"Interleukin 17"},{"ns":0,"exists":"","*":"Interleukin 22"},{"ns":0,"exists":"","*":"Interleukin 4"},{"ns":0,"exists":"","*":"Interleukin 5"},{"ns":0,"exists":"","*":"Interleukin 8"},{"ns":0,"exists":"","*":"Intraocular pressure"},{"ns":0,"exists":"","*":"Lamotrigine"},{"ns":0,"exists":"","*":"Leflunomide"},{"ns":0,"exists":"","*":"Leukocytes"},{"ns":0,"exists":"","*":"Lips"},{"ns":0,"exists":"","*":"Lymphocytes"},{"ns":0,"exists":"","*":"MHC class I"},{"ns":0,"exists":"","*":"MHC class II"},{"ns":0,"exists":"","*":"Macrophages"},{"ns":0,"exists":"","*":"Macules"},{"ns":0,"exists":"","*":"Maculopapular rash"},{"ns":0,"exists":"","*":"Major histocompatibility complex"},{"ns":0,"exists":"","*":"Malawian"},{"ns":0,"exists":"","*":"Mast cell"},{"ns":0,"exists":"","*":"Meninges"},{"ns":0,"exists":"","*":"Metabolism"},{"ns":0,"exists":"","*":"Methazolamide"},{"ns":0,"exists":"","*":"Minocycline"},{"ns":0,"exists":"","*":"Morbilliform"},{"ns":0,"exists":"","*":"Mucous membrane"},{"ns":0,"exists":"","*":"Mucous membrane of nose"},{"ns":0,"exists":"","*":"Mycoplasma"},{"ns":0,"exists":"","*":"N-acetyltransferase 2"},{"ns":0,"exists":"","*":"Natural killer T cell"},{"ns":0,"exists":"","*":"Natural killer cells"},{"ns":0,"exists":"","*":"Neutrophils"},{"ns":0,"exists":"","*":"Nevirapine"},{"ns":0,"exists":"","*":"Nonsteroidal anti-inflammatory drugs"},{"ns":0,"exists":"","*":"Off-target"},{"ns":0,"exists":"","*":"Oral mucosa"},{"ns":0,"exists":"","*":"Oxcarbazepine"},{"ns":0,"exists":"","*":"Oxicam"},{"ns":0,"exists":"","*":"Oxipurinol"},{"ns":0,"exists":"","*":"Parvovirus B19"},{"ns":0,"exists":"","*":"Pathophysiology"},{"ns":0,"exists":"","*":"Peptide"},{"ns":0,"exists":"","*":"Perforin"},{"ns":0,"exists":"","*":"Phenylbutazone"},{"ns":0,"exists":"","*":"Phenytoin"},{"ns":0,"exists":"","*":"Polymorphism (biology)"},{"ns":0,"exists":"","*":"Positive and negative predictive values"},{"ns":0,"exists":"","*":"Pseudoallergy"},{"ns":0,"exists":"","*":"PubMed Central"},{"ns":0,"exists":"","*":"PubMed Identifier"},{"ns":0,"exists":"","*":"Pustules"},{"ns":0,"exists":"","*":"Rhinitis"},{"ns":0,"exists":"","*":"Sepsis"},{"ns":0,"exists":"","*":"Serotype"},{"ns":0,"exists":"","*":"Serotypes"},{"ns":0,"exists":"","*":"Stem cells"},{"ns":0,"exists":"","*":"Steven Johnson syndrome"},{"ns":0,"exists":"","*":"Stevens\u2013Johnson syndrome"},{"ns":0,"exists":"","*":"Strontium ranelate"},{"ns":0,"exists":"","*":"Sulfasalazine"},{"ns":0,"exists":"","*":"Sulfonamide (medicine)"},{"ns":0,"exists":"","*":"Superinfection"},{"ns":0,"exists":"","*":"Systemic lupus erythematosus"},{"ns":0,"exists":"","*":"T-cell receptor"},{"ns":0,"exists":"","*":"TNFRSF12A"},{"ns":0,"exists":"","*":"TNFSF12"},{"ns":0,"exists":"","*":"TRAIL"},{"ns":0,"exists":"","*":"T cell"},{"ns":0,"exists":"","*":"T cell receptor"},{"ns":0,"exists":"","*":"T helper cells"},{"ns":0,"exists":"","*":"Th2 cells"},{"ns":0,"exists":"","*":"Toxic epidermal necrolysis"},{"ns":0,"exists":"","*":"Tumor necrosis factor alpha"},{"ns":0,"exists":"","*":"Type 1 diabetes mellitus"},{"ns":0,"exists":"","*":"Type III hypersensitivity"},{"ns":0,"exists":"","*":"Type II hypersensitivity"},{"ns":0,"exists":"","*":"Type IV hypersensitivity"},{"ns":0,"exists":"","*":"Type I hypersensitivity"},{"ns":0,"exists":"","*":"V(D)J recombination"},{"ns":0,"exists":"","*":"Viral latency"},{"ns":0,"exists":"","*":"Virus latency"}],"templates":[{"ns":10,"exists":"","*":"Template:Infobox medical condition (new)"},{"ns":10,"exists":"","*":"Template:Infobox"},{"ns":10,"exists":"","*":"Template:Template other"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":10,"exists":"","*":"Template:Main article"},{"ns":10,"exists":"","*":"Template:Main"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":828,"exists":"","*":"Module:Infobox"},{"ns":828,"exists":"","*":"Module:Navbar"},{"ns":828,"exists":"","*":"Module:InfoboxImage"},{"ns":828,"exists":"","*":"Module:String2"},{"ns":828,"exists":"","*":"Module:WikidataIB/sandbox"},{"ns":828,"exists":"","*":"Module:Complex date"},{"ns":828,"exists":"","*":"Module:I18n/complex date"},{"ns":828,"exists":"","*":"Module:Ordinal"},{"ns":828,"exists":"","*":"Module:Yesno"},{"ns":828,"exists":"","*":"Module:Roman"},{"ns":828,"exists":"","*":"Module:ISOdate"},{"ns":828,"exists":"","*":"Module:DateI18n"},{"ns":828,"exists":"","*":"Module:I18n/date"},{"ns":828,"exists":"","*":"Module:Calendar"},{"ns":828,"exists":"","*":"Module:I18n"},{"ns":828,"*":"Module:WikidataIB/i18n"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"},{"ns":828,"exists":"","*":"Module:Main"},{"ns":828,"exists":"","*":"Module:Hatnote"},{"ns":828,"exists":"","*":"Module:Hatnote list"},{"ns":828,"exists":"","*":"Module:Arguments"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"}],"images":["Lock-green.svg"],"externallinks":["//doi.org/10.1111/bjd.15423","//www.ncbi.nlm.nih.gov/pubmed/28256714","//doi.org/10.1007/s00281-015-0540-2","//www.ncbi.nlm.nih.gov/pubmed/26553194","//doi.org/10.1111/bcp.13294","//www.ncbi.nlm.nih.gov/pubmed/28345177","//www.ncbi.nlm.nih.gov/pmc/articles/PMC5486066","//doi.org/10.3390/ijms18061243","//www.ncbi.nlm.nih.gov/pubmed/28598363","//doi.org/10.1159/000453265","//www.ncbi.nlm.nih.gov/pubmed/27960170","//doi.org/10.1007/s12016-017-8654-z","//www.ncbi.nlm.nih.gov/pubmed/29188475","//www.ncbi.nlm.nih.gov/pmc/articles/PMC5487863","//doi.org/10.1007/s12325-017-0530-y","//www.ncbi.nlm.nih.gov/pubmed/28439852","//doi.org/10.2500/aap.2012.33.3561","//www.ncbi.nlm.nih.gov/pubmed/22794701","//doi.org/10.1097/PEC.0000000000001188","//www.ncbi.nlm.nih.gov/pubmed/28665896","//doi.org/10.1007/s11926-017-0626-z","//www.ncbi.nlm.nih.gov/pubmed/28138822","//www.ncbi.nlm.nih.gov/pmc/articles/PMC5000612","//doi.org/10.3390/ijms17081214","//www.ncbi.nlm.nih.gov/pubmed/27472323","//doi.org/10.1111/ijd.13434","//www.ncbi.nlm.nih.gov/pubmed/28084022","//doi.org/10.1016/S0140-6736(16)30378-6","//www.ncbi.nlm.nih.gov/pubmed/28476287","//www.ncbi.nlm.nih.gov/pmc/articles/PMC5733150","//doi.org/10.1155/2017/3186328","//www.ncbi.nlm.nih.gov/pubmed/29333460","//doi.org/10.1097/ACI.0000000000000286","//www.ncbi.nlm.nih.gov/pubmed/27362322","//doi.org/10.1111/1346-8138.13430","//www.ncbi.nlm.nih.gov/pubmed/27154258","//doi.org/10.1111/bjd.15498","//www.ncbi.nlm.nih.gov/pubmed/28346659","//www.ncbi.nlm.nih.gov/pmc/articles/PMC5133889","//doi.org/10.3390/ijms17111890","//www.ncbi.nlm.nih.gov/pubmed/27854302"],"sections":[{"toclevel":1,"level":"2","line":"Disorders","number":"1","index":"1","fromtitle":"Severe_cutaneous_adverse_reactions","byteoffset":5705,"anchor":"Disorders"},{"toclevel":2,"level":"3","line":"SJS, TEN, and SJS/TEN","number":"1.1","index":"2","fromtitle":"Severe_cutaneous_adverse_reactions","byteoffset":5721,"anchor":"SJS,_TEN,_and_SJS/TEN"},{"toclevel":2,"level":"3","line":"DRESS syndrome","number":"1.2","index":"3","fromtitle":"Severe_cutaneous_adverse_reactions","byteoffset":8036,"anchor":"DRESS_syndrome"},{"toclevel":2,"level":"3","line":"AGEP","number":"1.3","index":"4","fromtitle":"Severe_cutaneous_adverse_reactions","byteoffset":10973,"anchor":"AGEP"},{"toclevel":1,"level":"2","line":"Pathophysiology","number":"2","index":"5","fromtitle":"Severe_cutaneous_adverse_reactions","byteoffset":12574,"anchor":"Pathophysiology"},{"toclevel":2,"level":"3","line":"HLA proteins","number":"2.1","index":"6","fromtitle":"Severe_cutaneous_adverse_reactions","byteoffset":13246,"anchor":"HLA_proteins"},{"toclevel":2,"level":"3","line":"T cell receptors","number":"2.2","index":"7","fromtitle":"Severe_cutaneous_adverse_reactions","byteoffset":24786,"anchor":"T_cell_receptors"},{"toclevel":2,"level":"3","line":"ADME","number":"2.3","index":"8","fromtitle":"Severe_cutaneous_adverse_reactions","byteoffset":25869,"anchor":"ADME"},{"toclevel":2,"level":"3","line":"Other factors","number":"2.4","index":"9","fromtitle":"Severe_cutaneous_adverse_reactions","byteoffset":29314,"anchor":"Other_factors"},{"toclevel":3,"level":"4","line":"Virus reactivation","number":"2.4.1","index":"10","fromtitle":"Severe_cutaneous_adverse_reactions","byteoffset":29336,"anchor":"Virus_reactivation"},{"toclevel":3,"level":"4","line":"Infections","number":"2.4.2","index":"11","fromtitle":"Severe_cutaneous_adverse_reactions","byteoffset":30948,"anchor":"Infections"},{"toclevel":3,"level":"4","line":"Autoimmune Disorders","number":"2.4.3","index":"12","fromtitle":"Severe_cutaneous_adverse_reactions","byteoffset":31971,"anchor":"Autoimmune_Disorders"},{"toclevel":2,"level":"3","line":"Effectors of tissue injury","number":"2.5","index":"13","fromtitle":"Severe_cutaneous_adverse_reactions","byteoffset":32400,"anchor":"Effectors_of_tissue_injury"},{"toclevel":1,"level":"2","line":"Prevention","number":"3","index":"14","fromtitle":"Severe_cutaneous_adverse_reactions","byteoffset":34639,"anchor":"Prevention"},{"toclevel":1,"level":"2","line":"References","number":"4","index":"15","fromtitle":"Severe_cutaneous_adverse_reactions","byteoffset":37306,"anchor":"References"}],"parsewarnings":[],"displaytitle":"Severe cutaneous adverse reactions","iwlinks":[],"properties":[{"name":"wikibase_item","*":"Q55632923"}]}}